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ABSTRACT 
 
SHANNON Z. JONES: Novel Mechanisms of Regulating B cell responses During Adaptive 
Immunity                                                                                                                               
(Under the direction of Barbara J. Vilen) 
 
Initiation of the germinal center reaction during T-dependent adaptive immune 
responses gives rise to long-lived plasma cells (PCs) that produce high affinity, class 
switched antibodies. It also produces memory B cells to ensure a rapid, high affinity response 
to future pathogen exposure. Long-lived antibody and memory B cell responses underlie the 
success of vaccines and provide the host with durable, long-lasting protection from infectious 
disease.  Although, the formation and maintenance of memory B cells and plasma cells are of 
critical importance, the mechanisms regulating these processes are poorly understood. Our 
lab has been interested in understanding the role of dendritic cells in regulating the germinal 
center reaction and adaptive immune response.  We found that the formation of 
antigen/antibody immune complexes stimulate dendritic cells, through CD16 (FcgRIII), to 
secrete BAFF, a cytokine required initiation and maintenance of the germinal center as well 
as the formation of memory B cells. Specifically, our results indicate that DC-derived BAFF 
initially impacts the formation of T follicular helper cells, which are critical in seeding and 
initiating the germinal center response. Studies show that upon immunization with a T-
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dependent antigen, mice that lack CD16 expression, as well as mice lacking BAFF 
production by hematopoeitic cells, display reduced numbers of T follicular helper cells, and 
as consequence, reduced germinal center number and size.  Correlated with this deficit in 
germinal centers, these mice also display attenuated secondary immune responses, and fewer 
numbers of antigen-experienced memory B cells. This suggests that DCs and BAFF play a 
key role in germinal center dynamics and subsequent memory B cell formation and function. 
Collectively, our data highlight an additional role for BAFF in the initiation and maintenance 
of T-dependent adaptive immune responses. 
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CHAPTER 1 
Introduction  
 
1.1 Germinal Centers are the Hallmark of Adaptive Immunity  
T cell dependent adaptive immune responses generate high affinity, antigen-specific 
antibodies that provide the host with long-lived protection against recurring infection.  The 
ability of the immune system to generate such long-lasting responses is the basis for 
successful vaccination programs (1).  One of the most critical events in initiating the adaptive 
immune response is the formation of germinal centers (GCs).  Germinal centers are transient 
structures, located within B cell follicles of secondary lymphoid organs, where antigen-
activated B cells, proliferate, undergo affinity maturation, and give rise to memory B cells, 
and long-lived plasma cells (2). Dysregulation of cell proliferation, mutation, and 
differentiation within the germinal center can lead to various pathologies, including tumor 
development, autoimmunity, and immunodeficiency.  Therefore, understanding the 
mechanisms that regulate the survival, proliferation, and differentiation of B cells within the 
germinal center during T cell-dependent adaptive immune responses is of great importance.   
A.  Initiation of the germinal center response When naïve B cells bind antigen via the B 
cell receptor (BCR), they upregulate expression of the chemokine receptor, CCR7 and 
migrate to the outer T cell zones of secondary lymphoid organs, including the spleen and 
lymph nodes (3).   Once B cells have migrated, they engage in cognate interactions with 
 
2 
 
helper T cells (3) and can now choose one of two cell fates.  Specifically, these activated B 
cells can migrate into the extra-follicular space, under the influence of the G-protein coupled 
receptor, EBI-2 (4, 5), and differentiate into short-lived antibody secreting cells.  Most 
plasma cells generated during extra-follicular responses survive for approximately 3 days 
before undergoing apoptosis (6, 7).  Alternatively, activated B cells can move into the B cell 
follicle to establish germinal centers (8). The mechanisms responsible for this fate decision 
remain poorly understood, although several studies suggest that BCR affinity, BCR 
engagement, and co-stimulatory signals from helper T cells might all be involved (9-13).  
The initial germinal centers that are formed are oligoclonal, and are colonized on average, by 
one to three activated B cells within each follicle (14). Germinal center B cells differ from 
naïve B cells in many ways.  These cells are much larger and can be identified by their 
expression of Fas, or CD95, GL-7, binding to peanut agglutinin (PNA), and loss of surface 
IgD expression (15-17).  In the initial phase of the GC, there is extensive proliferation, or 
clonal expansion, but very little variation in the BCR. During this time, dark and light zones 
appear, which are thought to be sites of clonal expansion and selection, respectively (18). 
Intravital microscopy has shown that germinal center B cells can move between the dark and 
light zones (3).  During clonal expansion, the chemokine receptor, CXCR4, is 
downregulated, and germinal center B cells are no longer retained within the dark zone, by 
the chemokine, CXCL12 (3).  CXCL13 produced by follicular dendritic cell (FDCs) 
facilitates the trafficking of germinal center B cells to the light zone.  Thus, germinal center 
B cell migration can be bidirectional, depending on the concentration gradient of CXCL13 
and CXCL12 in each zone (19).  Germinal centers are now characterized as open structures, 
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including naïve follicular B cells that can enter the light zone (3), where they are tested for 
their ability to bind antigen by competing for surface antigen on FDCs.  
B.  Clonal Expansion, somatic hypermutation, and affinity maturation During the 
germinal center response, stromal FDCs and T cells generate the signals required for isotype 
switching, somatic hypermutation, memory B cell formation, and terminal differentiation 
into plasma cells (20). The affinity of serum antibody for foreign antigen increases over time, 
due to somatic hypermutations in the B cell receptor.  Most short-lived plasma cells in the 
extra-follicular foci are relatively unmutated.  In contrast, a high frequency of somatic 
hypermutations is evident in GC B cells (14, 21).  These B cells express the enzyme, 
activation-induced deaminase (AID), which deaminates cytidine residues in the VDJ and 
switch regions of the Ig gene, which leads to somatic hyper mutation and class switch 
recombination (22, 23). Clonal expansion of activated B cells followed by B cell receptor 
diversification, results in either retention of cells in the lymphoid organ and the formation of 
a second germinal center, or exit from the germinal center and entry into the long-lived 
memory B cell compartment (20).  Over time, the extra-follicular response wanes, while the 
long-lived plasma cells and memory B cells begin to appear. Finally, during the contraction 
of a primary immune response, long-lived plasma cells migrate to the bone marrow, while 
memory cells may enter into the periphery, as non-secreting, class-switched B cells.  
However a significant portion of the memory B cell pool remains within the secondary 
lymphoid organs, in close proximity to the marginal zone (24).  The antibody variable 
regions in most, but not all of long-lived PCs and memory cells display a high degree of 
mutations and show evidence of clonal selection, suggesting that these cells are derived from 
germinal centers (25, 26). The ultimate result of the germinal center is the generation of high-
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affinity, antigen-experienced B cells that will enter into circulation until re-encounter with 
antigen.  
C.  Factors that govern germinal center formation and maintenance.  Many factors 
govern the development and maintenance of the germinal center. Bcl-6 is highly expressed in 
germinal center B cells and is essential for their formation (27, 28).  Bcl-6 functions by 
binding to the regulatory regions of genes in GC B cells, ultimately inhibiting the DNA 
damage response and promoting rapid cell proliferation (29).  Another target of Bcl-6 is 
Prdm1, the gene encoding Blimp-1.  Suppression of Blimp-1 expression by Bcl-6 prevents 
plasma cell differentiation within the germinal center (30).  There is a large body of evidence 
indicating that signals from the BCR, from FDCs, and from T follicular helper (TFH) cells all 
contribute to germinal center B cell survival.  BCR signals support the survival of 
centrocytes (B cells undergoing selection within the light zone), since GC B cells that lack 
the BCR co-receptor, CD45, or the GTPase TC21, which links BCR signaling with PI3K 
activation, have increased rates of apoptosis (31).  TFH cells also provide proliferation, 
survival, and differentiation signals to GC B cells through CD40:CD40L interactions and the 
cytokines IL-4 and IL-21.  Although it is clear that CD40L is essential in mediating GC B 
cell survival, the cytokines and signals that are required for GC B cell differentiation into 
either long-lived plasma cells or memory B cells remain undefined. 
1.2 T follicular helper (TFH) cells 
T follicular helper (TFH) cells are the specialized subset of CD4+ T cells that are 
necessary for the initiation and GC maintenance, generation of memory B cells, and the 
development of plasma cells that arise from the GC reaction. TFH cells are characterized by 
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their constitutive expression of the transcription factor Bcl-6, as well as the expression of 
CXCR5, PD-1 and ICOS (32, 33).  The transcriptional repressor Bcl-6 is essential for TFH 
cell development, but it does not act alone in controlling TFH cell development.  A network of 
transcription factors is involved, including c-Maf, STAT3, Batf, and Bcl-6 all have roles in 
TFH cell differentiation and function (34, 35). It is postulated that Bcl-6 regulates TFH cell 
differentiation by repressing alternative differentiation pathways, including those of the Th1, 
Th2, or Th17 lineages (32).  Early Bcl-6 up-regulation occurs in the first division of activated 
CD4+ T cells, and is strongly induced by antigen presenting dendritic cells.  This first wave 
of Bcl-6 expression is observed within the first three days following antigen-priming at the B 
and T cell border and in the inter-follicular regions of lymph nodes in both mice and humans 
(36, 37). An additional wave of Bcl-6 expression coincides with CXCR5 induction and 
results in the development of a distinct BCL-6+CXCR5+ TFH cell population, independent of 
cognate B cell interactions (38).  In contrast to their induction, the maintenance of the TFH 
cell population in the follicle is dependent on cognate B cell interactions (37, 38).   
Once activated, TFH cells secrete IL-21, which has been shown to be the most potent 
cytokine involved in regulating plasma cell differentiation in mice and humans (39, 40). IL-
21 induction of plasma cell differentiation is STAT3 dependent (41), and involves the 
upregulation of Blimp-1, the master regulator of plasma cells (42, 43).  IL-21 is also 
important for optimal germinal center B cell proliferation.  The expression of Bcl-6 in GC B 
cells is somewhat reduced in the absence of IL-21 (44, 45).  In addition, IL-21 has been 
shown to be important for isotype switching to several IgG isotypes and it is suggested that 
IL-21 is the master regulator of class switching to IgG1 (46).  In addition to IL-21, TFH cells 
provide survival signals to GC B cells through additional pathways including CD40L, IL-4, 
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PD-1 and BAFF, which ultimately compete with death signals induced by Fas-FasL 
interactions (35).   
TFH cells are now defined as T cells that express the chemokine receptor CXCR5, 
localize to the follicles, and are specialized in providing help to germinal center B cells.  
Although TFH cells are one of the first identified T cell subsets, the nature of their formation 
and function has only recently begun to be defined.  Many of the cell surface molecules 
expressed by these specialized cells are critical for their interactions with B cells during the 
germinal center reaction.  CXCR5 is a defining molecule for T cells, which enables them to 
home to the B cell follicle. TFH cells migrate in response to CXCL13, produced by FDCs 
(35).  The migration of TFH cells into the follicle allows for the critical B cell-dependent 
phase of TFH cell differentiation to occur.  Activated B cells express ICOSL, and the 
expression of ICOSL by B cells is required for TFH cells.   ICOS-mediated PI3 kinase 
signaling is required for TFH cell differentiation, and for the production of IL-21 by TFH cells 
(47).  Global analysis of the gene expression profile in TFH cells has revealed that these cells 
are of a totally separate lineage from Th1 and Th2 cells (48).  For example, Bcl-6 is 
preferentially expressed by TFH cells, but not by Th1 or Th2 cells.   IL-21 is also preferentially 
expressed by TFH cells, and plays a critical role in regulation immunoglobulin production and 
germinal center formation (44, 49). 
 TFH cells provide germinal center B cells with survival and selection signals; therefore 
limiting the numbers of these cells is critical to prevent inappropriate B cell responses and 
the emergence of autoantibodies.  Little is known about the regulatory mechanisms that 
control these TFH cells.  A population of Foxp3+ follicular regulatory T cells have been 
identified that can exert suppressive effects on TFH cells and the germinal center response 
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(50, 51).  In response to immunization with T-dependent antigen, a potion of naïve regulatory 
T cells can express Bcl-6 (51).  Expression of Bcl-6 allows them to express CXCR5 and 
home to the B cells follicle and localize to the germinal center.  These T follicular regulatory 
cells control the germinal center reaction by limiting the number of TFH cells that are formed 
and by inhibiting the selection of non-antigen specific B cells, including those with self-
reactive B cell receptors (50).   
 Understanding mechanisms that regulate TFH cell differentiation and function is of 
great important for improved vaccine design, since nearly all approved human vaccines 
function on the basis of protective T-dependent immune responses.  In addition, TFH cells 
play important roles in common autoimmune diseases, such as systemic lupus erythematosus 
(SLE), since mice with expanded TFH populations and over-production of IL-21 develop 
lupus-like autoimmune disease (52).   
1.3  Formation and Maintenance of B cell memory 
The pool of quiescent, non-immunoglobulin secreting B cells that are produced 
during the germinal center reaction is largely composed of antigen specific, affinity-matured 
memory B cells. Some reported studies suggest that early memory B cell development can 
occur independent of a germinal center response (44, 53), although how well these germ-line 
BCR-expressing memory B cells compete with post-germinal center B cells during recall 
responses remains to be determined. Secondary responses resulting from re-challenge of 
memory B cells are faster, larger, and qualitatively different from primary responses (1).  The 
ability to mount a recall response can be maintained for decades in humans and through the 
majority of a rodent’s life (1).   
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 Many factors, such as antigen and cytokine availability, can affect the differentiation 
and survival of memory B cells.  The role of cognate antigen in memory B cell maintenance 
has been heavily debated.  It was originally shown that recall responses were attenuated over 
time after sorted memory B cells were transferred to naive recipients in the absence of 
antigen (54).  Based on this study, in addition to others, it was proposed that antigen 
containing immune complexes deposited on the surface of FDCs (via complement receptor 
and Fc receptors) was essential for memory cell maintenance (54, 55).  However, more 
recent studies by Shlomchik and colleagues have demonstrated that memory B cell survival 
and function is not dependent upon immune complex deposition on FDCs (56).  Rajewsky 
and colleagues have also demonstrated that there is no requirement for continued exposure to 
antigen to sustain memory B cells.  Specifically, the BCR of memory B cells can be altered 
to recognize an antigen that has never been encountered by the host and memory B cells 
would continue to persist (57). The basis of the controversy and conflicting data surrounding 
the factors required for memory B cell maintenance could result from the fact that there are 
multiple layers of B cell memory, with each layer consisting of multiple effector function.  
Sophisticated studies by Dogan et. al have demonstrated that the memory B cell compartment 
can be composed of several layers, consisting of an antigen-independent layer located outside 
of the B cell follicles, in the spleen, blood, and secondary lymphoid organs. It also consists of 
an antigen-dependent layer of proliferating centroblasts in GC-like structures that depend on 
the presence of antigen (58).  The authors have shown that after challenge, the IgG+ memory 
cells have an immediate effector and protective response (the hallmark of B cell memory).  
This subset seems to have little capacity to reinitiate a GC response.  In contrast, the IgM+ 
subset of B cell memory ensures the replenishment of the memory compartment, by its rapid 
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mobilization and immediate isotype switching to IgG.  In this model, the memory 
compartment is able to quickly neutralize the invading antigen, while continuing to replenish 
the memory pool.  Other studies have also confirmed a hierarchy of maturity with the 
memory B cell compartment in mice (59).  These studies demonstrated that there is a 
spectrum of memory B cells, consisting of a progression from more naïve-like to more 
memory-like properties. 
Although we understand the basic features of the adaptive immune response, the 
signals that are required for memory B cell formation and reactivation are still relatively 
unknown.  The mechanisms that regulate the quality and quantity of the memory population 
are also unclear.  To date, no single factor has been identified irrefutably as being essential 
for memory formation.  A recent study has hinted towards a role for IL-21 and BAFF in 
regulating memory B cell formation in humans (39).  However, there are contrasting studies 
in mice demonstrating that memory B cell survival is independent of BAFF (60).   
1.4 The role of BAFF in adaptive immunity 
The TNF family member, BAFF and its homologue, APRIL, are homotrimeric type II 
transmembrane proteins that are necessary for B cell homeostasis. It was previously believed 
that only cells of a myeloid origin produced BAFF. It is now known that in addition, non-
hematopoietic stromal cells can secrete BAFF and APRIL, which provide local niches to 
modulate the survival and function of B cells and plasma cells, especially in the bone marrow 
(61-63). BAFF producing cells include monocytes, macrophages, neutrophils, activated T 
and B cells, FDCs, stromal cells, astrocytes, osteoclasts, and epithelial cells (64, 65).  The 
expression of BAFF is increased in the presence of type one interferons, IL-10, and G-CSF, 
 
10 
 
CD40L, as well as by the activation of Toll-like receptors (TLR4 and TLR9) (64, 65). 
Although it can be found in a membrane bound form, BAFF is usually produced in soluble 
form as a result of furin cleavage (61, 65).  In myeloid cells, the binding of immune 
complexes also increases BAFF processing through an Fc receptor-dependent mechanism 
(66, 67).  Processed, soluble BAFF adopts a trimeric form, as seen with other TNF family 
members; but it is the only member capable of further assembly as a 60-mer (65).  BAFF has 
been shown to bind to three receptors, BCMA, BAFF-R (BR3), and TACI, all of which are 
expressed on B cells.  BCMA is preferentially expressed on plasma cells, plasmablasts and 
tonsillar germinal center B cells (65). TACI is expressed by all peripheral B cells, 
particularly marginal zone B cells and B-1 B cells (65). BR3 is the dominant BAFF receptor 
expressed on all mature murine and human B cells.  In mice, the expression of BAFF-R is 
initially low on newly formed immature B cells, but increases during B cell maturation.   
BAFF-R is the key receptor that is responsible for BAFF-mediated B cell survival, as mice 
deficient in BAFF-R display a phenotype similar to that of BAFF deficient mice (61).  
BCMA-deficient mice display no abnormalities in immune function, aside from impaired 
survival of long-lived plasma cells in the bone marrow (68).  TACI, in contrast, has emerged 
as a negative regulator of B cell activation and expansion, since B cell numbers are increase 
in TACI deficient mice.  In addition, TACI deficient mice also eventually develop SLE-like 
disease and lymphoid cancers (69).  
It has been well documented that BAFF has an important role in B cell homeostasis.  
For reasons that are not fully understood, this homeostasis requires BAFF that is produced by 
radio-resistant stromal cells, instead of bone marrow-derived cells (70).  BAFF and BR3 are 
known to play a fundamental role during the transition from immature T1 to T2 B cells and 
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therefore the generation of the mature B cell compartment in the spleen.  This was 
demonstrated by an almost complete lack of follicular and marginal zone B cells and by a 
block at the T1 cell stage in BAFF/BAFF-R deficient mice (71).  In these mice, the B-1 
compartment was unaffected, indicating that the development of this B cell subset is 
independent of BAFF and BAFF-R signaling.  In contrast, transgenic mice over-expressing 
BAFF display an increase in all B cell subsets (72). This suggests that all mature B cells 
express BAFF receptor on their surface and are capable of responding to BAFF. The 
expanded B cell compartment in BAFF Tg mice also corresponded with the onset of 
autoimmunity and lupus-nephritis like disease (72). Recent studies have demonstrated a role 
for BAFF in plasma cell survival, however, memory B cell survival is independent of BAFF 
(60, 73).  There is no current literature addressing whether BAFF plays a role in either 
plasma cell or memory cell differentiation. 
The role of BAFF in germinal center formation and maintenance has been 
controversial.  Given that BAFF-/- mice have a deficit in mature B cells, one would predict 
that the ability to form germinal centers would be compromised.  Surprisingly, BAFF and 
BAFF-R deficient mice have the ability to form germinal centers subsequent to challenge 
with antigen.  However, the kinetics of the germinal center reaction were altered in these 
mice (74).  Studies have shown that immunized BAFF-R deficient and BAFF deficient mice 
displayed normal numbers of germinal centers early on in the immune response; however, 
the germinal centers dissipated more rapidly than wild type mice (74).  There was also an 
increase in frequency of smaller germinal centers and decline in larger germinal centers, 
indicating the quickened dissipation of germinal center structures (64, 74).  The lack of 
germinal center stability was attributed the failure to develop a competent FDC reticulum and 
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lack of antigen stimulation (74). These results suggest that BAFF receptor signaling is 
required for germinal center maintenance and that BAFF is also required for the formation of 
the FDC reticulum and efficient antigen stimulation of B cells.   
A. An Emerging Role for BAFF in Modulating T cell responses  Although BAFF and its 
cognate receptors have a dominant role in B cell biology, it is now clear that either directly, 
or indirectly, BAFF can also modulate T cell function in vitro and in vivo. Several in vitro 
studies have confirmed the role of BAFF as a co-stimulatory and survival factor for activated 
T cells (75). In addition to providing survival signals, BAFF also impacts T cell activation.  
In the presence of suboptimal T cell receptor stimulation, BAFF enhances T cell proliferation 
and cytokine production (76-78). Neutralization of BAFF in vitro, using both TACI-Ig and 
BAFF-R-Ig, resulted in decreased T cell activation.  In addition, BAFF deficient mice show 
impaired T cell mediated graft rejection.  These studies suggest that physiological levels of 
BAFF are necessary for the generation of sufficient T cell responses.   BAFF may also play a 
role in stimulating T cell function during T cell mediated pathogenesis.  Studies by Mackay 
et al have shown that the over-expression of BAFF in BAFF Tg mice exacerbates the 
severity of Th1-mediated delayed-type hypersensitivity responses, by enhancing T cell 
proliferation and IFN-g production in lymph nodes (79).  Although a role for BAFF has been 
demonstrated in modulating Th1 responses, it remains to be determined whether BAFF is also 
involved in regulating other T cell subsets, including T follicular helper (TFH) cells.  
B.  BAFF and autoimmunity.  Elevated levels of soluble BAFF have been found in the sera 
and target organs of disease in mouse models of SLE, collagen induced arthritis, and 
chemically induced autoimmunity (80-82).  Similarly, high levels of serum BAFF have been 
found in a subpopulation of human patients with varying autoimmune diseases (83).  In many 
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studies, BAFF levels have been correlated with increased disease activity and titers of 
pathogenic autoantibodies (84). These studies provide a strong case for the pathogenic role of 
excess BAFF and APRIL in autoimmune disease.  
The pathogenic role of BAFF in autoimmunity is further evidenced by the therapeutic 
benefits of BAFF neutralization.  Studies have shown that lupus-prone mice treated with 
TACI-Ig and BAFF-R Ig displayed less proteinuria, and as a result, prolonged survival.  In 
vivo BAFF antagonism has also provided protection in murine models of other autoimmune 
diseases, including rheumatoid arthritis, multiple sclerosis, and Graves’ disease (63, 85-87).    
Neutralization using TACI-Ig and BAFF-R Ig is thought to have therapeutic effects, due to B 
cell depletion, similar to what has been observed with anti-CD20 immunotherapy 
(Rituximab).  Blocking BAFF may have some distinct advantages over B cell depletion using 
Rituximab. For example, BAFF receptor and CD20 expression overlap in many B cell 
subsets, but they also differ in other populations, including plasma cells, which express 
BCMA, but not CD20 (84).    B cell depletion using anti-CD20 therapy also results in 
elevated serum BAFF levels (88).  Therefore, newly generated immature B cells could be 
exposed to high levels of BAFF, which could cause another breakdown of immune tolerance 
and the resurgence of autoimmunity.  Therefore the risk of another breach in immune 
tolerance could be avoided by targeting BAFF in the treatment of SLE and other autoimmune 
disease.   
Treatment of lupus-prone mice with TACI-Ig and BAFF-R Ig resulted in the 
depletion of both follicular and marginal zone B cell subsets, but did not affect immature B 
cells or the B-1 B cell subset Interestingly, in vivo BAFF neutralization does not impact the 
survival of memory B cells in wild type mice (60).  However, the effects of BAFF 
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neutralization on memory B cell formation have not yet been addressed.  Elucidating the role 
of BAFF in maintaining memory B cell function will be especially important in regulating B 
cell memory formed to self-antigens, in the setting of autoimmune disease.   
1.5  Systemic Lupus Erythematosus (SLE) 
Systemic lupus erythematosus (SLE) is a complex, multi-organ autoimmune disease, 
affecting approximately 250,000 Americans, and is characterized by the production of 
autoantibodies to nuclear components (89-91).  Alternating periods of flares and remissions 
are associated with an increased burden of apoptotic cells, the formation and deposition of 
immune complexes, and subsequent inflammation (92).  Although the etiology of SLE 
remains unknown, multiple defects in immune regulation have been identified in lupus-prone 
mice and SLE patients.  These include, complement deficiencies, T cell receptor (TCR) 
signaling abnormalities, and defective cytokine secretion (89, 92-94).  These defects have 
been shown to contribute to the onset and pathogenesis of SLE (95).   It is likely that 
environmental factors act on genetically prone individuals to induce a breakdown in 
tolerance mechanisms that regulate autoreactive lymphocytes. Some of these environmental 
factors include exposure to air pollutants and cigarette smoke, heavy metal poisoning (96), 
and previous viral infections, including Epstein Barr virus (97, 98).  Hormonal influences 
have also been implicated, with SLE primarily affecting women (10:1 ratio). Genetic 
differences and environmental factors may interact in the pathogenic processes and also 
influence disease development and course.  Identification of these factors and their 
interaction is vital to understanding the disease and may also contribute to the identification 
of new treatment targets, and possibly aid in disease prevention.   
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1.6  IgG Fc Receptors  
IgG Fc receptors link innate and adaptive immune responses by their ability to 
mediate cellular interactions with antigen-antibody immune complexes.  Two general classes 
of IgG FcRs are now recognized by the presence of an activating ITAM motif within the 
cytoplasm, and the inhibitory receptor, characterized by an ITIM sequence (99-102). These 
two classes of receptors function in concert and are usually co-expressed on the cell surface.  
The co-engagement of both the activating and inhibitory signaling pathways set the 
appropriate thresholds, which ultimately balances protective and pathogenic effector 
responses after IgG immune complex engagement.   Imbalances between activating and 
inhibitory FcγR functions can contribute to autoimmunity and other pathologies in both mice 
and humans (103). 
A.  ITAM-containing, Activating Fc Receptors There are three different activating FcγRs 
expressed on murine effector cells: FcγRI (CD64), FcγRIII (CD16), and the recently 
described FcγRIV (also identified as CD16-2) (101).   All three receptors generate signals 
through the ITAM sequences found within a shared common γ chain subunit (FcγR).  
Expression of the common γ chain is critical for the assembly of the activating Fc receptors 
(100).  Common gamma chain knockout (Fcγ-/-) mice were shown to have significant defects 
in antibody-dependent effector responses, including ADCC, phagocytosis of immune 
complexes, and some inflammatory responses (104). In contrast, deletion of the individual 
activating Fc receptors showed less pronounced phenotypes, especially in responses 
involving IgG2a and IgG2b antibody isotypes (105). These activating Fc receptors are found 
on most effector cells, including macrophages, monocytes, dendritic cells, NK cells, mast 
cells, eosinophils, neutrophils, and are absent from lymphoid cells (100, 102, 104, 106, 107). 
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The only high-affinity Fcγ receptor in both humans and mice, FcγRI, binds IgG2a in mice, or 
IgG1 and IgG3 in humans, with an affinity of 108 – 109 M-1.  All other receptors have a 100-
1000 fold lower affinity, and show broader specificities (107).  IgG1 is the only isotype that is 
consistently assigned to an individual activating Fc receptor, FcγRIII.  The deletion of 
FcγRIII abrogates IgG1-mediated effector functions in many models of pathogenesis, 
including arthritis, glomerulonephritis, IgG-dependent anaphylaxis, IgG-mediated hemolytic 
anemia, and immunothrombocytopenia (108-112).  FcγRIV binds with intermediate affinity 
to IgG2a and IgG2b in vitro (103).   Studies have shown that even if several of activating Fc 
receptors with the same isotype specificity are present on the same cell surface, only those Fc 
receptors will be engaged that show the optimal affinity for the respective isotype.  
Therefore, IgG1 immune complexes will trigger only FcγRIII, since it is the only activating 
Fc receptor that can bind IgG1 (106). 
B.  FcγRIIb, the single ITIM-containing, inhibitory Fc Receptor  In contrast to the 
activating FcγRs, FcγRIIb (or CD32) contains an ITIM sequence that inhibits effector cell 
responses (102). In addition to its expression on B cells, where it is the only IgG Fc receptor, 
FcγRIIb is also expressed on neutrophils, macrophages and mast cells, and is absent on T and 
NK cells (101).  FcγRIIb expression on the surface of B cells is critical in setting BCR 
signaling thresholds and B cell effector functions. Signaling within the ITIM motif of 
FcγRIIb results in the recruitment of the phosphatases, SHIP and SHP-1, which prevents the 
recruitment of kinases such as BTK or PLCγ to the cell membrane, thereby diminishing 
events that are downstream of BCR activation such as intracellular calcium fluxes (107).  
The importance of FcγRIIb in modulating B cell activity and immune tolerance is supported 
by several studies in both mice and humans.  Studies using FcγRIIb-/- mice showed enhanced 
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B cell responses, autoimmunity, and augmented IgG-mediated inflammation, demonstrating 
the inhibitory role of FcγRIIb in immune responses (113).    
C.  Fc receptors mediate important effector functions in immune cells  Fcγ receptors play 
a significant role in vivo in maintaining peripheral tolerance, in augmenting T cells responses 
through antigen presentation, and in mediating antigen recognition and effector cell 
activation.  Although Fc receptors have many roles in linking innate and adaptive immunity, 
their role in promoting secondary adaptive immune responses has only recently began to 
emerge.  A recent study has shown that immune complex binding by Fc receptors enhances 
secondary antibody responses, although the precise mechanism by which this occurs is 
unknown (114).  Immune complex binding by Fc receptors can induce many effector cell 
functions, including cytokine production and phagocytic functions.  It remains unclear how 
these effector functions impact secondary immunity. 
1.7  The role of TGF-β  in maintaining peripheral immune tolerance  
The immune system has evolved to initiate robust responses to invading pathogens 
while maintaining tolerance to self-antigens.  Multiple mechanisms exist to ensure normal 
immunological function.  The removal of self-reactive B and T cells during development 
creates a repertoire within the periphery that will preferentially recognize and eliminate non-
self-antigens (115-117).  Although central tolerance mechanisms exist within the bone 
marrow and thymus to eliminate autoreactivity, there is clear evidence that self-reactive 
immune cells can enter the periphery and secondary lymphoid organs. Therefore, peripheral 
tolerance mechanisms must also exist to limit the activation of autoreactive lymphocytes.  
Regulatory T and B cells, and their secreted cytokines have been recently recognized as 
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essential components of peripheral tolerance (118, 119).   Transforming growth factor β 
(TGF-β) is one such regulatory cytokine with a critical role in regulating immune responses 
to self.   
TGF-βs are regulatory proteins with pleiotropic effects on cell proliferation, 
differentiation, migration and survival, which affect many biological processes, including 
development, carcinogenesis, fibrosis, wound healing, and immune responses (120).  The 
generation and analysis of TGF-β deficient mice established the role of the cytokine in 
inhibiting inflammation and autoimmunity, and has fostered an interest in this cytokine in 
immune regulation (121, 122).  The immunoregulatory role of TGF-β was demonstrated in 
null mice. TGF-β-/- mice that are born, die shortly after weaning as a result of severe 
inflammatory disease, with lymphocyte infiltration into multiple organs and autoimmune 
disease (122, 123).  The identification of the receptors for TGF-β s and the Smad proteins, as 
mediators of signaling, has also provided much needed information on the role of TGF-β s in 
regulating immune responses.   
TGF-β is an important regulator of B cells activity, as demonstrated by the phenotype 
of mice with a B cell specific inhibition of TGF-β signaling (124).  Secretion of TGF-β by 
regulatory cells inhibits B cell proliferation, induces apoptosis of immature or resting B cells, 
BCR activation, and isotype switching to most IgG isotypes.  Consistent with TGF-β 
mediated inhibition of IgG class switching, conditional deletion of TGF-β signaling in B 
cells, in vivo, resulted in elevated serum Ig.  These mice also developed enhanced IgG3 
responses to a normally weak antigen (124).  These studies implicate TGF-β in attenuating B 
cell responses to low affinity antigens.  Interestingly, titers of anti-DNA antibodies were also 
increased in mice lacking B cell derived TGF-β signaling, which suggests that TGF-β is an 
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important regulator of B cell tolerance to self-antigens in vivo (124).  In contrast to its 
inhibitory roles in immune function, TGF-β has a unique role in promoting switching to IgA 
and IgG2b in murine B cells and IgA in human B cells, in vitro (124-126). Upon optimal 
stimulation with antigen, and cytokine stimulation, the inhibitory activity of TGF-β subsides, 
and TGF-β can strongly promote IgA secretion.  TGF-β mediated IgA class switching is 
associated with increased transcription of alpha heavy chain transcripts.  The role of TGF-β 
in IgA production is further demonstrated in mice with a condition deletion of TGF-β 
signaling in B cells, where there is almost a complete absence of IgA within the serum (124).  
Thus, similar to T cells, TGF-β has both inhibitory and stimulatory effects on B cell function.  
The adaptive immune response gives rise to long-lived humoral responses that protect 
the host from recurring infection.  Although dendritic cells indirectly promote adaptive 
immunity through antigen presentation, it remains unclear whether DCs actively shape these 
responses.  The goal of the work described herein is to identify mechanisms by which DC 
cells may impact the long-lived plasma cell response and memory B cell formation that 
occurs during T cell-dependent adaptive immune responses. 
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CHAPTER 2 
CD16-mediated BAFF production promotes Bcl-6 expression  
 
2.1 Introduction 
The success of adaptive immune responses requires appropriate interactions between 
antigen specific B and T cells leading to germinal center (GC) responses (1, 2).  The 
specialized microenvironment provides sites for rapid expansion and mutation of antigen-
specific B cell clones, antibody isotype switching, and finally commitment to the plasma cell 
fate or memory B cell pool (3-5).  The formation of GCs and the emergence of memory B 
cells are subsequent to the production of antibody induced by T-independent formation of 
extrafollicular foci (2, 6), suggesting that early antibody responses may play a role in early 
GC events.  
The affinity matured memory B cells that emerge from the GC require T cell help. 
Recent studies have identified CD4+ follicular helper T cells (TFH) as critical effectors that 
provide help to B cells during the GC response (7, 8). The formation of TFH cells is 
dependent on the expression of Bcl-6 and the attenuation of Blimp-1, which inhibits the 
differentiation of other TH subsets (7, 9).  TFH cells are distinguished from other CD4+ 
subsets in that they express CXCR5, ICOS, PD-1, and IL-21.  TFH cells are important in 
forming and maintaining the GC.  Together with follicular dendritic cells, TFH cells provide 
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the proliferative and survival signals that are necessary to expand antigen-specific B cells and 
form the emerging germinal centers (10).   
In addition to regulating T cell effector function, Bcl-6 is also highly expressed in 
germinal center B cells and is essential for their formation (11, 12).  Bcl-6 binds to the 
regulatory regions of genes in GC B cells, ultimately inhibiting the DNA damage response 
and promoting rapid proliferation within the germinal center (13).  Another target of Bcl-6 is 
Prdm1, the gene encoding Blimp-1.  Suppression of Blimp-1 expression by Bcl-6 prevents 
plasma cell differentiation in the germinal center (14). Because Bcl-6 upregulation mediates 
several B and T cell effector functions that are critical for the germinal center reaction, the 
factors that promote Bcl-6 expression are of great interest. Mitogenic signals (including anti-
mu, LPS, PMA and ionomycin and CD40L) that promote B and T cell proliferation are 
known to induce Bcl-6 expression using in vitro culture systems (15).  Few studies have 
addressed the mechanisms that regulate Bcl-6 expression in vivo.  IL-21 signaling has been 
linked to Bcl-6 expression in CD4+ T cells and GC B cells, although the expression of Bcl-6 
was only marginally reduced in the absence of IL-21 (16, 17).  Thus, other factors exist to 
regulate Bcl-6 expression within B and T cells, germinal center formation, and other key 
events of the adaptive immune response.     
 Because of its essential role in B cell survival and homeostasis (18), BAFF may have 
additional roles in the adaptive immune response. Although BAFF and its cognate receptors 
have a dominant role in B cell biology, it is now clear that either directly, or indirectly, BAFF 
can also modulate T cell function in vitro and in vivo (19). In addition to providing survival 
signals, BAFF also impacts T cell activation.  In the presence of suboptimal T cell receptor 
stimulation, BAFF enhances T cell proliferation and cytokine production (20-22). It is likely 
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that because of its effects on B and T cell function in vivo, BAFF can also impact the 
germinal center.  Previous reports have shown that the role of BAFF in the dynamics of the 
germinal center is complex and controversial. Relatively little is known about the role of 
BAFF in GC formation, generation of the B cell memory compartment, and plasma cell 
development. A single study using TACI-Fc to reduce serum BAFF levels, reported a 
complete lack of germinal centers in treated mice (23).  In complete contrast, a study using 
BCMA-Fc as a mechanism BAFF blockade, in vivo, show that germinal center formation is 
independent of BAFF (24).  Therefore, the role of BAFF in germinal center dynamics 
remains unclear.   
 During adaptive immune responses, DCs play an important role in activating T cells 
through their ability to present peptides.  In this study, we show that DCs actively shape early 
events in the adaptive immune response, by sensing a productive early antibody response and 
secreting BAFF.  We find that BAFF induces the expression of Bcl-6 in activated B cells 
thereby extinguishing the plasma cell program and committing the cells to the memory 
pathway.  Simultaneously, BAFF promotes the expression of Bcl-6 in activated CD4+ T cells, 
promoting TFH cell differentiation. Overall our studies define ICs sensed by DCs as critical 
initiators of the GC response and through their production of BAFF, they promote memory B 
cell differentiation.
 
34 
 
2.2 Materials and Methods 
Animals 
All animals were maintained in an accredited animal facility at University of North Carolina. 
C57BL/6 (B6) and CD16-/- mice were bred in house and used at 8-10 weeks of age.  5-7 
week old B6-Ly5.2 congenic mice were purchased from NCI-Frederick.  OTII TCR 
transgenic mice were obtained from Jenny Ting at the University of North Carolina (UNC).  
BAFF-/- mice were obtained from Glenn Matsushima, also from UNC.   BAFF Tg mice were 
obtained from Dr. Jeffrey Rathmell of Duke University. 
Reagents and Antibodies 
Antibodies against mouse CD4, CD19, CD95, GL-7, ICOS, and PD-1 were purchased from 
Biolegend.  Anti-CXCR5, anti-B220, anti-IgG1, IgG2a, IgG2b, and IgG3 antibodies were 
purchased from BD Biosciences.  Anti-mouse Bcl-6 was purchased from Santa Cruz.  
Recombinant cytokines, IL-4 and IL-5 were purchased from Peprotech.  NP-OSu was 
purchased from Biosearch Technologies.  KLH and ovalbumin proteins were purchased from 
Sigma Aldrich.  The adjuvant, alum, was purchased from Thermo Scientific.  Anti-mu F(ab)2 
antibody was purchased from Jackson Immunoresearch.  Anti-mu (B7.6), anti-NP (H33L and 
B1-8), and AC-38 anti-idiotype antibodies were purified from hybridoma supernatants.  
H33L and B1-8 were kind gifts from Dr. Garnett Kelsoe (Duke University).  BR3-Fc and 
IgG-Fc were kind gives from Dr. Robert Benschop (Eli Lilly). B and T cell negative 
selection purification kits were purchased from StemCell Technologies.  Splenic DC 
purification kit was purchased from Miltenyi Biotec.  Streptavidin-alkaline phosphatase was 
purchased from Southern Biotech.   
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B cell purification 
Splenic B cells were isolated from B6 mice by negative selection (StemCell Technologies). B 
cells were 95-99% pure, as determined by flow cytometry (with fewer than 5% DCs and 
MFs).  
Bone marrow-derived DC (BMDC) cultures 
Bone marrow single-cell suspensions were prepared from the tibias and femurs of B6,  
CD64-/-, CD32-/-, CD16-/-, and BAFF-/-mice.  Following RBC lysis, cells were cultured in 
GM-CSF and IL-4 for 7 days in a 24 well low cluster dish.   
Splenic DC isolation 
CD11c+ cells were purified from the spleens of B6 mice at 8-10 weeks of age.   CD11c+ DCs 
were approximately 80% pure, as determined by flow cytometry.   
B cell and DC co-culture 
1.5 X 105 purified B6 B cells were co-cultured with 1 X 104 BMDCs or ex vivo DCs in a 96 
well plate for 7 days.  B cells were stimulated with IL-4, IL-5 and anti-mu.  Supernatants 
were harvested and IgM secretion was measured by ELISA.   
B6 B cell and  OTII T cell co-culture 
2 X 105 purified B6 B cells were co-culture with 2 X 105 T cells purified from OTII TCR 
transgenic mice.  Cells were cultured or 7 days in the presence of 100 µg ovalbumin (with or 
without 1 X104 B6 BMDCs).  Supernatants were harvested on day 7 and IgM was measured 
by ELISA. 
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Preparation of DC Conditioned Media (CM) 
2 X 104 BMDCs were cultured in a 96 well plate, in the presence of anti-mu (B7.6), 
conditioned media from antigen-stimulated B cells, IL-4 and IL-5. After seven days, 
supernatants from stimulated DCs were harvested.  C67BL/6 B cells were purified, and 
cultured with or without DC CM (20% of total volume), in a 96 well plate, with additional 
anti-mu (B7.6), IL-4 and IL-5. 
Total IgM ELISAs 
IgM levels from were detected using anti-mouse IgM (33-60) and biotin-labeled anti-mouse 
IgM (B7.6). 
CFSE-based Proliferation Assay 
B cell proliferation was assessed by the dilution of 5-carboxyfluorescein diacetate 
succinimidyl ester (CFSE) loaded cells as previously described (25). 
Bone Marrow Chimeras 
B6-Ly5.2 congenic mice (6-8 weeks of age) were lethally irradiated (1050 rads), and 
reconstituted with 8 X 106 bone marrow stem cells from either wildtype (B6) or BAFF-/- 
mice.  Reconstitution of the B cell compartment was assessed after 8 weeks, by flow 
cytometry. 
NP-KLH Immunization 
8-10 week old B6, BAFF-/- bone marrow chimeras, and CD16-/- mice were immunized i.p. 
with 100 µg NP-11-14-KLH precipitated in alum for induction of primary responses.  For 
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secondary immunization, mice were boosted (i.v. injection) with the same dose of soluble 
NP11-14-KLH at least 30 days post- primary immunization.  Mice were bled weekly for serum 
anti-NP levels.  Antibody levels were measured 4, 7, 14 days after boost to quantitate 
memory recall (secondary) responses.  Additional cohorts of B6 and CD16-/- mice were 
immunized s.c. with 100 µg NP-KLH precipitated in alum.  8 X 106 BAFF Tg or B6 BMDCs 
were adoptively transferred into immunized mice.  Inguinal lymph nodes were harvested at 
seven days post-immunization and assessed by flow cytometry. 
Memory B cell Enumeration 
B6 and CD16-/- mice (8-10 weeks of age), and B6 and BAFF-/- chimeras were immunized as 
described.  At 28 days post-immunization spleens were harvested from B6, CD16-/-, b6 
chimeras, and BAFF-/- chimeras.  Single-cell suspensions were prepared, and antigen specific 
memory B cells were enumerated by flow cytometry.  Antigen-specific, IgG+ memory B 
cells were detected using the AC-38 hybridoma and biotinylated anti-IgG cocktail 
(containing anti-IgG1, anti-IgG2a, anti-IgG2b, and anti-IgG3).  
T Follicular Helper Cell Enumeration 
B6 and CD16-/- mice (8-10 weeks of age), and B6 and BAFF-/- chimeras were immunized as 
described.  At day 7 post-immunization, the mice were sacrificed and spleens were harvested.  
Single cell suspensions were prepared, and CD4+, CXCR5+, PD-1+, and ICOS+ T cells were 
enumerated by flow cytometry.   
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NP ELISA 
Sera were tested for IgG anti-NP Abs (ELISA). Microtiter plates were coated with NP13-
conjugated BSA (Biosearch Technologies). Serially diluted serum samples were incubated 
overnight at 4oC. Anti-NP IgG levels were detected using an alkaline phosphatase conjugated 
goat anti-mouse IgG antibody (1/1000 dilution) followed by phosphatase substrate (Sigma-
Aldrich).  Optical density (OD) values were converted to concentration based on standard 
curves (generated using the H33L anti-NP hybridoma), using a four-parameter logistic 
equation (Softmax Pro 3.1 software; Molecular Devices). 
AID Real Time PCR 
Spleens were harvested from B6 and BAFF-/- chimeras seven days after NP-KLH 
immunization, and splenic B cells were isolated according to the Stem Cell Easy Sep 
protocol.  mRNA was isolated from 5-10 X 106 purified B cells using  TRIzol (Invitrogen) 
and chloroform.  cDNA from 500 ng of mRNA per sample was synthesized using 
Superscript VILO cDNA Synthesis Kit (Invitrogen).  DNA amplification was performed 
using FastStart Universal SYBR Green Master mix (Roche).  Primers for qRT-PCR were 
synthesized by IDT. The PCR protocol was 95° for 10 minutes, and 40 cycles at 95° for 15 
seconds and 60° for 1 minute.  Relative values were compared using the 2-ΔΔCΤ method. 18s 
rRNA was used as an internal control in all experiments.  
Germinal Center Staining and Counting 
Spleens were harvested from B6 or CD16-/- mice on days 7, 14, and 21 after NP-KLH 
immunization and flash frozen in OCT (Fisher).  Sections 6mm thick were fixed in 1:1 
MeOH/Acetone, blocked with 10% FBS in PBS plus 1:100 2.4G2, and stained with PNA-
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biotin (Sigma) and B220-APC (BD Pharmingen), and Streptavidin-Alexa488 (Invitrogen).  
Germinal centers were recognized as aggregates of PNA+ B cells.  The percent of total 
splenic area covered by germinal centers, as well as average number and average size of 
germinal centers were compared between B6 and CD16-/- mice.  
Architecture Staining for B6 and BAFF-/- Chimeras 
Spleens were prepared as above from naïve B6, B6 chimera, or BAFF-/- chimera mice.  
Sections of 8mm thickness were cut, fixed in MeOH/Acetone, blocked in Superblock 
(Pierce) plus 1:100 2.4G2, and stained with anti-B220-APC, anti-CD11b-PE, anti-CD11c-
PE, and Thy1.2-biotin (all BD Pharmingen), followed by Strepdavidin Alexa 488 
(Invitrogen).  
Statistics 
The one sample t test was used to compare levels of secreted IgM levels in anti-mu 
stimulated controls, and anti-mu stimulated B cells under various treatment conditions.  The 
one sample t test was also used to compare expression levels of Bcl-6 in B6 and BAFF-/- 
bone marrow chimeras. The student’s t test was used to compare levels of secreted IgM and 
IgG in immunized B6 mice, CD16-/- mice, and B6 and BAFF-/- bone marrow chimeras.  The 
unpaired t test was used to compare percentages of memory B cells, GC B cells, and  TFH 
cells.  Analyses were performed in GraphPad Prism. 
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2.3 Results 
2.3.1 Dendritic cells regulate Ig secretion from antigen stimulated B cells 
 During adaptive immune responses, the presentation of antigen to primed T cells 
promotes the differentiation of activated B cells into memory and plasma cells suggesting 
that dendritic cells (DCs) play an indirect role in humoral immune responses.  To address 
whether DCs play a more direct role in shaping the B cell response to foreign antigen, we co-
cultured bone marrow derived DCs (BMDCs) with ovalbumin-stimulated B cells from B6 
mice and antigen-pulsed OTII T cells ( Figure 2.1 A).  We found that BMDCs inhibited 98% 
of Ig secretion induced by ovalbumin stimulation.  Inhibition of Ig secretion required OTII T 
cells and was ovalbumin-specific as BSA did not promote Ig secretion.  Furthermore, B cells 
cultured with ovalbumin alone did not secrete a detectable amount of Ig.  Repression of Ig 
secretion was not unique to ovalbumin in that BMDCs also repressed 85% of anti-mu 
induced Ig where T cell help was provided in the form of recombinant IL-4 and IL-5 (Figure 
2.1 B). Similar to BMDCs, splenic CD11c+ ex vivo cells repressed 70% of anti-mu induced 
immunoglobulin (Figure 2.1 B).  B cell proliferation and viability were comparable to that of 
B6 B cells stimulated in the absence of DCs (data not shown). 
The binding of immune complexes (ICs) to Fc receptors on DCs can induce cytokine 
production (26).  In our in vitro model, IgG-ICs could form when secreted IgM binds to the 
anti-mu antibody (B7.6) used to stimulate the B cells in culture.  Since B7.6 is an IgG1 
antibody, the IgM/anti-mu containing ICs could ligate FcγRs on the DCs. To assess whether 
DCs secrete cytokines in response to Fc receptor ligation, we prepared DC conditioned 
medium (CM) by stimulating BMDCs for 7 days with the culture supernatant from anti-mu 
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(B7.6) or anti-mu (Fab)2 -stimulated B cells (Figure 2.1 C). We then tested whether these DC 
CMs repressed antigen-stimulated B cell Ig secretion. We found that DC CM containing the 
intact Fc portion significantly inhibited Ig secretion, indicating that DCs secrete a soluble 
factor(s) that represses B cell Ig secretion.  This is consistent with transwell data showing 
that DCs regulate Ig secretion in a contact-independent manner (data not shown).  In contrast, 
DC CM prepared using the anti-mu F(ab)2 was unable to inhibit IgM secretion in stimulated 
B cells (Figure 2.1 C).  This suggests that the binding of ICs to FcγRs on DCs inhibits IgM 
secretion. To determine which Fc receptors were responsible for the observed DC-mediated 
repression, we prepared a series of conditioned media, using BMDCs from B6, CD64  
(FcγRI-/-), CD32 (FcγRIIb)-/-, and CD16 (FcγRIII)-/- mice. The data show that CM from 
CD16-/- mice was unable to repress B cell Ig secretion, while CMs from B6, CD64-/-, and 
CD32-/- mice remained repressive (Figure 2.1 D). Thus, the binding of anti-mu/IgM 
containing ICs to CD16 induces the secretion of a soluble repressive factor(s) that limits the 
differentiation of B cells into antibody secreting cells.  
To discern whether DCs decreased Ig secretion by inhibiting the Ig transcriptional 
program, we measured the intracellular levels of XBP-1, IRF-4, and Bcl-6.  Coincident with 
reduced Ig secretion, we found that the levels of XBP-1 and IRF-4 were diminished two-fold, 
while Bcl-6 was increased 1.5-fold (Figure 2.1 E-G). This suggests that DCs block activated 
B cells from differentiating into plasma cells and may affect the PC/memory fate decision.  
Thus, the binding of IgG-ICs to CD16 induces the secretion of a soluble factor(s) that 
upregulates Bcl-6 and limits the differential of B cells into plasma cells.  
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2.3.2 Immunized CD16-/- mice have impaired secondary immune responses 
 Our transcription factor analysis suggests that the stimulation of DCs through CD16 
directs the differentiation of activated B cells away from plasma cell towards the memory B 
cell program, or germinal center. To address these possibilities, we measured primary and 
secondary antibody responses over time in B6 and CD16-/- mice following immunization and 
boost with NP-KLH. We found that immunized CD16-/- mice mounted an IgM and IgG 
primary antibody response that was comparable to B6 mice (Figures 2.2 A and C). In 
contrast, IgM levels during the secondary response of immunized CD16-/- mice were reduced 
2-fold, while the IgG antibody levels were 6-fold decreased (Figures 2.2 B and D).  
Collectively, these data suggest that immune complex binding and CD16 are critical for IgG 
and IgM production during secondary immune responses.  
2.3.3 CD16-/- mice have diminished numbers of memory B cells  
 Rapid, high titer secondary immune responses require the activation of memory B 
cells.  We reasoned that the defects observed in the recall response of CD16-/- mice are the 
result of defects in memory B cell formation.  To address whether CD16 plays a role in 
forming B cell memory, we enumerated CD19+, IgG+, AC-38-binding (idiotype positive) B 
cells 28 days following immunization.  As predicted, immunized B6 mice showed a 4-fold 
expansion of CD19+, IgG+ antigen specific memory B cells, as compared to unimmunized 
controls (Figure 2.3).  In contrast, CD16-/- mice showed very little expansion (1.5-fold) and 
compared to immunized B6 mice, the numbers of memory B cells were reduced by 59% 
(Figure 2.3). These results show that CD16 influences the secondary immune response prior 
to the formation of memory B cells. 
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2.3.4  Immunized CD16-/- mice exhibit defects in forming GCs 
 Memory B cells are a hallmark of a successful germinal center response.  Thus, the 
diminished numbers of memory cells could reflect the failure to form or maintain germinal 
centers (GCs). To assess whether loss of CD16 diminishes the entry of B cells into GCs, we 
enumerated GL-7+, CD95+ splenic B cells 7 days following immunization. As shown in 
Figure 2.4, immunized B6 mice showed a three-fold increase in the numbers of GC B cells, 
compared to unimmunized B6 mice.  However, CD16-/- mice showed only a two-fold 
increase in GC B cells, compared to unimmunized CD16-/- mice (Figure 2.4 A and B).  
CD16-/- had 50% fewer GL7+, CD95+, CD19+ B cells, when compared to immunized B6 
mice.  Furthermore, the immunized CD16-/- showed a reduction in the number of AC-38 
binding, antigen-specific B cells within the germinal center (Figure 2.5).  Taken together, our 
data indicate that the CD16-/- mice harbor defects in germinal center formation. 
 To determine the size and frequency of germinal centers, spleen tissue sections were 
stained with peanut agglutinin (PNA) and the B cell marker, B220.  The numbers of GCs per 
follicle were counted and the size of GC was measured in B6 compared to CD16-/- mice. We 
found that 7 days after immunization, GCs in the spleens of CD16-/- mice were 40% smaller 
than those in B6 mice and over the course of the next 2 weeks (day 14, 21) the GC size never 
reached that achieved in B6 mice (Figure 2.6 A and C).  On day 28, the GCs were 
significantly smaller in both B6 and CD16-/- mice indicating the small size observed in 
CD16-/- spleens was not due to delayed maturation (data not shown). Immunized CD16-/- 
mice also displayed fewer GCs within the B cell follicle at days 7 and 14, although this 
difference was not statistically significant. Figure 2.6 B).  These data suggest that CD16 is 
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also necessary to initiate the germinal center.  Our data implicate the importance of events 
early in germinal center formation in defining the memory B cell pool.   
2.3.5 Dendritic cells secrete BAFF in response to CD16 ligation 
Fc receptor activation induces DCs to secrete a number of cytokines (27, 28).  To 
define the underlying mechanism by which ICs, DCs, and CD16 regulate memory cell 
formation and GCs, we neutralized CM from DCs, using a panel of antibodies, whose 
cognate receptors are expressed on B cells. Neutralization with BR3-Fc, a decoy receptor for 
BAFF, showed a significant loss of repression, restoring antibody secretion to levels 
comparable to the control (Figure 2.7).  Furthermore, DCs from BAFF-/- deficient mice were 
unable to repress anti-mu induced Ig secretion. Finally, treatment of anti-mu stimulated B 
cells with rBAFF significantly decreased IgM secretion (Figure 2.7). This suggests that DC-
derived BAFF, induced by ICs, regulates B cell responses in vitro.       
2.3.6 BAFF-/- bone marrow chimeras also have reduced secondary responses  
Our data reported thus far suggest that activated B cells may rely on DCs and their 
ability to sense ICs and secrete BAFF to direct B cells towards the germinal center and into 
the memory B cell pool.  Although BAFF has been implicated in the survival of mature, 
naïve B cells, and plasma cells, it has not been implicated in regulating the formation of B 
cell memory. To assess whether BAFF produced by hematopoietic cells plays a role in 
adaptive immune responses, we examined primary and secondary immune responses of 
reconstituted B6 and BAFF-/- chimeras.  BAFF-/- mice lack mature peripheral B cells, while 
reconstituted BAFF-/- bone marrow chimeric mice have mature B cells (29), with all 
hematopoietic cells lacking BAFF production.  Although immunized BAFF-/- chimeras have 
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a comparable primary anti-NP response to that of B6 mice (29), their response to secondary 
immunization with NP-KLH has not been assessed. Similar to the CD16-/- mice, BAFF-/- 
chimeras displayed comparable levels of anti-NP IgG and IgM antibody levels to B6 during 
the primary response (2.8 A and C).  However, the BAFF-/- bone marrow chimeras showed 
an impaired secondary response to NP-KLH immunization, with approximately 2-fold less 
IgM and IgG production (Figures 2.8 B and D).  BAFF can induce class switching in 
activated B cells (30-32), hence the loss of IgG in the secondary response could reflect 
diminished AID expression.  Comparison of AID mRNA levels in B6 and BAFF-/- chimeras 
showed comparable levels of AID expression (Figure 2.9) Overall, the data indicate that 
BAFF derived from hematopoeitic cells is essential for secondary immune responses.   
Because we saw only a 50% decrease in antibody responses by the BAFF-/- chimeras, other 
factors may be involved in regulating secondary immune responses, and could contribute to 
the 6-fold decrease in the anti-NP response of the CD16-/- mice. 
2.3.7 Enforced expression of BAFF in DCs restores secondary responses in CD16-/- mice. 
The data suggest that activated B cells may rely on DCs to direct memory cell 
formation through their ability to sense ICs and secrete BAFF.  To directly assess DC-
derived BAFF was necessary for GC formation, we adoptively transferred (s.c.) BMDCs 
from BAFF transgenic mice into immunized CD16-/- mice to determine whether GC B cell 
(CD19+, GL-7+, CD95+) numbers were restored.  We previously established that 70% of 
subcutaneously injected BMDCs migrate to the inguinal lymph and that the magnitude of the 
subcutaneous anti-NP response was comparable to intraperitoneal immunization. Using this 
model, we found that immunized B6 mice showed a robust increase (4.8 fold) in GC B cells, 
as compared to the unimmunized control mice (Figure 2.10).  Consistent with the 
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intraperitoneal immunization model, CD16-/- mice displayed fewer GC B cells (2.3 fold), as 
compared to immunized B6 mice.  The transfer of BMDCs chronically expressing BAFF 
restored this defect. This effect was not due to increased numbers of DCs as BMDCs derived 
from B6 mice did not restore GC B cell numbers, as compared to immunized B6 mice 
(Figure 2.10).  Overall, these data indicate that BAFF from DCs restores GC B cell numbers 
in immunized CD16-/- mice. 
2.3.8 BAFF-/- chimeras have decreased formation of memory B cells and a delayed 
germinal center response 
To assess whether memory B cells formed in the absence of hematopoietic cell-derived 
BAFF, we enumerated antigen-specific CD19+, IgG+, and AC-38+ B cells on day 28, post-
immunization.  We found that there was a 4-fold increase in memory B cells in immunized 
B6 chimeras.  In contrast, BAFF-/- showed a significantly diminished increase in memory B 
cells and this level was reduced by 45% fewer memory B cells compared to immunized B6 
chimeras (Figure 2.11 A).  To determine whether BAFF also affects GC formation, we 
enumerated CD19+, GL-7+, and CD95+ B cells, seven days post-immunization.  Compared to 
B6 chimeras, those lacking BAFF displayed 30% fewer germinal center B cells (Figures 2.11 
B and C).  Thus, early in the primary response, the numbers of memory and GC B cells is 
impaired in BAFF-/- chimeras, much like the phenotype observed in the CD16-/- mice.  This 
implicates BAFF secretion by DCs in the entry of activated B cells into the GC. 
2.3.9  CD16-/- mice and BAFF-/- chimeras have reduced TFH cells 
The development of TFH cells is an important step in promoting B cell responses 
during adaptive immunity.  TFH cells co-express CXCR5, ICOS, and PD-1 allowing them to 
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properly home to GCs, to influence selection and survival (33).  Defects in the differentiation 
of this T cell subset could account for the reduced germinal size and memory B cell numbers 
in CD16-/- mice and BAFF-/- chimeras.  Further, our data indicate that in vitro, BAFF 
regulates Bcl-6.  To define whether BAFF affects TFH cells, B6 and CD16-/- mice were 
immunized with NP-KLH, sacrificed at day 7, and TFH cells were enumerated. CD16-/- mice 
had 54% fewer CD4+, CXCR5+, PD-1+ T cells, as compared to immunized B6 mice (Figure 
2.12 A and B). This was not a consequence of secondary effects due to CD16 deficiency 
since BAFF-/- chimeras also exhibited a 40% decrease in numbers of TFH cells (Figure 2.12 C 
and D).   
We predicted that if BAFF regulated the formation or maintenance of TFH cells, 
forced expression of BAFF in the DC population would restore the TFH cell pool.  Indeed, the 
adoptive transfer of BAFF transgenic BMDCs into immunized CD16-/- mice restored the 
number of TFH cells at seven days post-immunization to levels that were not statistically 
different from immunized B6 mice (Figure 2.13). This effect was not observed in immunized 
CD16-/- mice that received BMDCs from B6 mice, indicating that increased numbers of DCs 
alone does not enhance TFH cell numbers. Collectively, this suggests that BAFF, induced by 
ICs activating CD16 promotes the formation or maintenance of TFH cells.   
2.3.10 BAFF regulates the expression of Bcl-6 
The upregulation of Bcl-6 by CD4+ T cells promotes expression of CXCR5 and ICOS 
on TFH cells, while expression in activated B cells extinguishes the PC program and directs 
activated B cells toward memory B cell pathway.  ICOS has been shown to regulate Bcl-6 in 
TFH cells, but whether other factors impact Bcl-6 remains unclear.  We reasoned that since 
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BAFF increased Bcl-6 expression in our in vitro culture model, it might affect Bcl-6 
expression in the GC response.  We found that at day 7 post-immunization, Bcl-6 levels in 
CD4+ T cells of BAFF-/- chimeras were reduced by 43% (Figure 2.14 A).  BCl-6 expression 
in GC B cells in BAFF-/- chimeras was also reduced by a similar magnitude (Figure 2.14 B).  
Thus, the diminished numbers of TFH cells and GC B cells is coincident with reduced Bcl-6 
expression.  
To define whether constitutive expression of BAFF by DCs restores Bcl-6 levels, we 
adoptively transferred BAFF Tg BMDCs into immunized CD16-/- mice by subcutaneous 
expression. We found that at day 7 post-immunization, enforced expression of BAFF by DCs 
Bcl-6 expression was restored Bcl-6 comparable to that of immunized B6 mice (Figure 2.15 
A).  Constitutive expression of BAFF by DCs also restored the Bcl-6 levels in GC B cells 
(Figure 2.15 B).  The data show that in the absence of FcR stimulation and BAFF expression, 
Bcl-6 expression is reduced.  As a consequence GC size and memory B cell numbers are 
reduced.  This defect ultimately results in diminished recall responses. 
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2.4 Discussion 
Proper execution of an adaptive immune response requires T cells, antigen presenting 
cells, such as DCs, and B cells.  The current dogma is that DCs prime T cells to promote B 
cell Ig secretion.  In this paper, we highlight a novel role for DCs in sensing a productive 
immune response through Fc receptors, followed by secreting BAFF to direct B cells towards 
the seeding of a germinal center.  Our data show that BAFF is a critical factor in the 
formation of TFH cells and diminished numbers of TFH cells delay the number and size of 
newly forming germinal centers.  As a consequence, the number of memory B cells is 
reduced, leading to a significant reduction in antibody levels during recall responses. These 
findings place an important role on DCs in defining the fate of activated B cells and identify 
BAFF as an important mediator that initiates the B cell memory response.  Our studies 
indicate that DCs exert these regulatory effects through the sensing of a productive immune 
response via immune complex binding through Fc receptors. Upon Fc receptor activation, 
DCs secrete BAFF, which plays a critical role in initiating T follicular cell formation and 
subsequent germinal center formation.  We also demonstrate the requirement for Fc receptor 
ligation and subsequent BAFF production in memory B cell differentiation.  
Receptors for the Fc portion of IgG play a significant role in vivo in maintaining 
tolerance, augmenting T cells responses via antigen presentation, and in mediating effector 
cell activation during immune responses.  We’ve now identified an additional role for the Fc 
receptor, CD16, in regulating germinal center formation and subsequent secondary immune 
responses through the production of BAFF by myeloid cells.  Recent studies by Goins et al. 
support our findings, and also implicate Fc receptors in enhancing secondary immune 
responses. Although these studies linked Fc receptors and the enhancement of memory B 
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responses, the exact mechanism by which this occurs is still undefined.  Furthermore, these 
studies did not define the specific Fc receptor involved in this regulatory process, since Fcγ-/- 
mice lack CD64, CD16, and CD16-2. From our studies, we have concluded that expression 
of a single Fc receptor, CD16, and its activation by immune complexes is required for DCs to 
regulate B cell responses in vitro and in vivo.  Specifically, ligation of CD16 by immune 
complexes allows for the production of BAFF, which is critical for germinal center 
formation, TFH cell differentiation, and downstream B cell effector function. 
Although multiple Fc receptors are expressed on the surface of DCs, with varying 
affinities for IgG, our in vitro data suggest that only CD16 is critical in this mechanism.  The 
implication of only CD16 can most likely be attributed to the fact that it preferentially binds 
the immune complexes generated in our in vitro cultures, which were composed of IgG1.   
Several studies corroborate our findings and have reported the preferential binding of CD16 
to IgG1-containing immune complexes in both in vitro and in vivo systems (34-36). Because 
NP immunization results primarily in an IgG1 response, it is likely that CD16 predominantly 
binds the ICs formed in vivo to induce regulatory immune functions.  Although our work 
suggests that CD16 is indispensable for TFH cell generation and germinal center responses, it 
is possible that immune responses that generate antibodies of another isotype will implicate 
an additional Fc receptor.  
During T-dependent adaptive immune responses, B cells interact with TFH cells 
within the follicle and these cellular interactions are indispensable for germinal center 
formation and the production of class-switched, high affinity antibodies.  Consistent with 
their location in the B cell follicle, TFH cells upregulate the chemokine receptor, CXCR5, 
allowing for migration toward the ligand CXCL13, which expressed exclusively in the 
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follicle.  ICOS is also upregulated on TFH cells and is required for their development and 
expansion.  In addition, IL-21 has been reported to play a critical role in TFH cell formation 
and in B cell growth, survival, and class switching (17).  Although, TFH cell differentiation is 
dependent on the availability of IL-21 (37), other cytokines could also be important in 
regulating T follicular helper TFH cell fate.  We herein report that myeloid cell-derived BAFF 
also regulates T follicular helper differentiation.  We have found that mice that lack CD16 
expression and BAFF production by hematopoietic cells have reduced numbers of TFH cells, 
following immunization.  As a consequence, we also saw a temporal defect in germinal 
formation, and an additional defect in memory B cell differentiation.  This delay in germinal 
center formation and defect in secondary B cell responses were similar to defects seen in IL-
21R deficient mice immunized with T-dependent antigens (38), wherein there was a delay at 
post-immunization day 7 in germinal center formation and a significant reduction in total 
antigen specific memory B cells at day 35 post-immunization.  Thus, CD16 and BAFF 
appear to be as equally important as IL-21 in regulating TFH cell function and adaptive 
immune responses.  Most recently, Ettinger and colleagues have shown that BAFF and IL-21 
synergize to enhance the formation of memory B cells in humans (39).  Thus, it is possible 
that BAFF and IL-21 signaling integrate to contribute the adaptive immune responses and the 
generation of B cell memory 
Our studies provide evidence of a direct molecular mechanism by which BAFF 
signaling impacts TFH cell formation.  Upregulation of the transcription factor Bcl-6 is also a 
key requirement for TFH cell differentiation and germinal center initiation (40).  We propose 
that BAFF plays a role in promoting the formation of TFH cells and the seeding of the 
germinal center reaction, by impacting Bcl-6 expression in both B and T cells. It is possible 
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that BAFF/BAFF-R interactions lead to additional molecular changes that promote TFH cell 
differentiation.  A previous study has shown that BAFF-R signaling can induce NFkB 
activation and subsequent ICOSL expression in B cells, which is required for TFH cell 
formation (41).  Thus, signaling through the BAFF receptor may be necessary for the 
upregulation of cell surface receptors and molecules, such as CXCR5 and ICOS, that are 
required for the differentiation and function of TFH cells.  Overall, our results ultimately 
demonstrate that BAFF regulates T-dependent adaptive immune responses by initially 
impacting the differentiation of TFH cells immediately following antigen encounter. 
 BAFF has been established as a key cytokine in primary B cell survival and 
homeostasis.  However, recent studies have revealed a complex role for this cytokine in the 
germinal center reaction. A few conflicting studies have been published describing the role of 
BAFF in germinal center formation and maintenance.  In studies using BR3-deficient mice, 
Kalled and colleagues have shown BAFF is not required for the initiation of the GC 
response, however, it is necessary for the maintenance of established GCs (42). The authors 
also report an increase in small germinal centers and a decline in large germinal centers, 
indicating an overall dissipation (42, 43).  The authors attribute the lack of GC stability in 
BR3-deficient mice to failure of the mice to develop a mature FDC reticulum.  However, 
other factors may contribute to the effects of BAFF on germinal center maintenance. In stark 
contrast, Yan et. al showed that the BAFF-TACI interaction is critical for germinal center 
formation.  Specifically, they found that spleens from immunized, TACI-Fc-treated mice 
were devoid of germinal centers (23).  These conflicting results could be due to the fact that 
different immunizing antigens were used (sRBCs vs. NP-CGG), in addition to the fact that 
germinal center reactions were assessed at varying time points.  The observed differences 
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could also be attributed to the BAFF-depleting reagent that was used (BCMA-Fc vs. TACI-
Fc). The complete absence of germinal centers in immunized, TACI-Fc treated mice could 
implicate a role for APRIL, since both BAFF and APRIL can bind TACI in vivo.  The lack of 
GCs in immunized TACI-Fc mice might also implicate an additional, unidentified TACI 
ligand that regulates germinal center formation.  Similar to studies by Yan et al, our 
experiments reveal a role for both Fc receptors and BAFF production in initiating the 
germinal reaction.  We found that both CD16-/- and BAFF-/- chimeras had a delay in germinal 
center formation.  Germinal centers in immunized CD16-/- mice were also significantly 
smaller than those in immunized control.  Our data suggest that early events in the germinal 
center define are essential for formation of the memory B cell pool.   Because B cells in 
CD16-/- have a shorter duration in the germinal center, it is also likely that the length of the 
germinal center response is critical in forming high affinity, antigen-experienced memory B 
cells. 
 Although survival and maintenance of the mature B cell compartment is dependent 
upon BAFF production by radiation resistant stromal cells, our data suggest that certain 
aspects of the adaptive immunity rely on BAFF produced by hematopoietic cells. 
Specifically, TFH cell differentiation, germinal center initiation, and memory B cell formation 
all rely on hematopoietic stem cell-derived BAFF.  Our data suggest that although serum 
BAFF levels in BAFF-/- chimeras are comparable to B6 chimeras, high local concentrations 
of BAFF within the spleen are required for efficient germinal center formation and memory 
B cell formation. 
 Overall, our studies highlight a role for dendritic cell-derived BAFF in regulating 
multiple events during the adaptive immune response.   Activation of dendritic cells through 
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a CD16-mediated mechanism leads to BAFF production, which promotes Bcl-6 expression 
with B cells and germinal center formation.  BAFF also actively shapes the development of 
TFH cells by modulating Bcl-6 expression in CD4+ T cells. In addition to its role early in the 
germinal center response, BAFF also impacts memory B cell formation and subsequent recall 
responses. 
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Fig. 2.1 DCs secrete soluble factors that inhibit Ig secretion and PC programming. 
Fig. 2.1 DCs secrete soluble factors that inhibit Ig secretion.  (A.) Purified B6 B 
cells were co-cultured with OTII TCR Tg T cells, and either ovalbumin or BSA (+ B6 
BMDCs). Ovalbumin stimulated B cells secreted 1.2-2 µg/mL IgM.  n = 3 (B.) 
Purified B6 B cells were co-cultured with either B6 DMDCs or B6 ex vivo DCs in the 
presence of anti-mu, rIL-4, and rIL-5. Anti-mu stimulated B cells secreted 15-31 
µg/mL IgM.  n=5 (C. ) B6 B cells were cultured with DC CM (containing either anti-
mu with intact Fc or anti-mu F(ab)2) in the presence of additional anti-mu, rIL-4 and 
rIL-5. n=5  (D.).  Purified B6 B cells were cultured with DC CM from B6, CD64-/-, 
CD32-/-, or CD16-/- mice.  n=5. Culture supernatants were harvested after seven days.  
Total IgM levels were quantitated by ELISA.  * p < 0.05, one sample t test 
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Fig. 2. 1  DCs secrete soluble factors that inhibit Ig secretion. Purified B6 B cells 
were stimulated with anti-mu, rIL-4, and rIL-5 for 48 hrs (+ B6 DC DC). Cells were 
harvested permeabilized, and intracellular expression levels of (E.) IRF-4, (F.) XBP-1, 
and (G.) Bcl-6 were assessed by flow cytometry.  Data are representative of 3 individual 
experiments. 
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Fig. 2. 2 CD16-/- mice  have defective secondary immune responses.
Fig. 2. 2 CD16-/- mice  have defective secondary immune responses.  B6  and 
CD16-/- mice were immunized with 100 µg NP-11-KLH in alum (i.p).  Mice were 
bled weekly and primary antibody responses (A and C) were measured by ELISA.  
At 35 days post-immunization, the mice were boosted with 100 µg soluble NP-
KLH, and antibody secretion during the secondary immune response was assessed 
at days 4, 7, and 14 post-boost (B and D). n = 9 for each group.  *p < 0.05, 
Student’s t test 
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Fig. 2.3 Immunized CD16-/- mice have a diminished number of Ag-specific memory B cells.
Fig. 2.3 Immunized CD16-/- mice have fewer Ag-specific memory B cells.  (A. and B.)  
8-10 week old B6 and CD16-/- mice were immunized with NP-14-KLH.  At 28 days post-
immunization, spleens were harvested and CD19+, IgG+, AC-38-binding B cells were 
enumerated by flow cytometry. *p < 0.05, unpaired t test 
    
  
 
59 
 
Fig. 2.4 Immunized CD16-/- mice have a diminished number of GC B cells.
 
Fig. 2.4 Immunized CD16-/- mice have fewer GC B cells.  (A. and B.)  8-10 week old 
B6 and CD16-/- mice were immunized with NP-14-KLH precipitated in alum.  At 7 days 
post-immunization, spleens were harvested and CD19+, GL-7+, CD95+ B cells were 
enumerated by flow cytometry.  * p < 0.05, unpaired t test 
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Fig. 2.5 Immunized CD16-/- mice have a diminished number of Ag-specific B cells within the 
germinal center.
Fig. 2.5 Immunized CD16-/- mice have fewer Ag-specific B cells within the GC.  8-
10 week old B6 and CD16-/- mice were immunized with NP-14-KLH precipitated in 
alum.  At 7 days post-immunization, spleens were harvested and AC-38-binding, 
CD19+, GL-7+, CD95+ B cells were enumerated by flow cytometry.   * p < 0.05, **p < 
0.01, n.s:  not significant, unpaired t test 
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Fig. 2.6 Immunized CD16-/- mice have smaller GCs.
Fig. 2.6 Immunized CD16-/- mice have smaller GCs.  8-10 week old B6 and CD16-/- 
mice were immunized with NP-14-KLH.  At 7 days post-immunization, spleens were 
harvested, sectioned, immunofluorescently stained with anti-B220 (red) and anti-PNA 
(green) to assess germinal center number (B.) and size (C.) n= 7 * p < 0.05., n.s: not 
significant, unpaired t test 
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Fig. 2.7 Dendritic cells secrete BAFF in response to CD16 ligation to inhibit Ig secretion.
Fig. 2.7  Dendritic cells secrete BAFF to inhibit Ig secretion.  (A.) Anti-mu 
stimulated B6 B cells were cultured with B6 DC CM neutralized with BR3-Fc or 
control antibody, IgG-Fc.  Purified B6 B cells were also cultured with from either 
B6 or BAFF-/- mice in the presence of additional anti-mu, rIL-4 and rIL-5. n=4. 
Finally, anti-mu stimulated B cells were cultured with 10 ng/mL rBAFF.  Culture 
supernatants were harvested after seven days.  Total IgM levels were quantitated by 
ELISA.  * p < 0.05, one sample t test 
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Fig. 2.8 BAFF-/- chimeras  have defective secondary immune responses.
Fig. 2.8 BAFF-/- chimeras  have defective secondary immune responses.  B6 
and BAFF-/- chimeras were immunized with 100 µg NP-11-KLH in alum (i.p).  
The mice were bled weekly and primary antibody responses (A and C) were 
measured by ELISA.  At 35 days post-immunization, the mice were boosted with 
100 µg soluble NP-KLH, and antibody secretion during the secondary immune 
response was assessed at days 4, 7, and 14 post-boost (B and D). *p < 0.05, 
Student’s t test 
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Fig. 2.9 BAFF-/- chimeras express comparable levels of AID.
 
murine Aicda 
forward 
5’‐GGGAAAGTGGCATTCACCTA‐3’  
murine Aicda 
reverse 
5’‐GAACCCAATTCTGGCTGTGT‐3’ 
murine 18s rRNA 
forward 
5’‐TCAAGAACGAAAGTCGGAGGTT‐3’ 
Murine 18s rRA 
reverse 
5’‐GGACATCTAAGGGCATCACAG‐3’ 
Table 2.1 Real Time RT-PCR primer sequences 
Fig. 2.9 BAFF-/- chimeras express comparable levels of AID.  B6 and BAFF-/- 
chimeras were immunized with 100 µg NP-11-KLH in alum (i.p).  At seven days 
post-immunization, B cells were purified from the spleen and RNA was isolated.  
Expression of AID were quantitated by real time RT-PCR.  n=3.  n.s:  not 
significant, one sample t test 
___ n.s. 
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Fig. 2.10  DC-derived BAFF restores GC response in immunized CD16-/- mice.
 
Fig. 2.10  DC-derived BAFF restores GC response in CD16-/- mice.   BMDCs were 
prepared from B6 and BAFF Tg mice.  B6 or BAFF Tg BMDCs were subcutaneously 
injected into CD16-/- mice, immunized with NP-14-KLH.  Inguinal lymph nodes were 
harvested seven days post-immunization, and assessed for the presence of CD19+, GL-
7+, CD95+ GC B cells by flow cytometry.   *p < 0.05, n.s:  not significant, unpaired t test 
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2.11 Immunized BAFF-/- chimeras have a diminished number of memory B cells and GC B 
cells.
2.11 Immunized BAFF-/- chimeras have fewer memory and GC B cells.  
Reconstituted B6 and BAFF-/- chimeras were immunized with NP14-KLH precipitated in 
alum.  (A).  At 28 days post-immunization, spleens were harvested and CD19+, AC-38 
binding, IgG+ memory B cells were enumerated by flow cytometry.  (B. and C.)  At 
seven days post-immunization, CD19+, GL-7+, CD95+ GC B cells were enumerated by 
flow cytometry. * p < 0.05, **p < 0.01, unpaired t test 
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2.12 Immunized CD16-/- mice and BAFF-/- chimeras have a diminished number of TFH cells.
2.12 Immunized CD16-/- mice and BAFF-/- chimeras have fewer TFH cells.  8-10 week 
old B6 and CD16-/- mice were immunized with NP-14-KLH precipitated in alum.  (A and 
B)  At 7 days post-immunization, spleens were harvested and CD4+, CXCR5+, an PD-1+ T 
cells were enumerated by flow cytometry. * p < 0.05, ** p < 0.01, unpaired t test 
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2.12 Immunized CD16-/- mice and BAFF-/- chimeras have fewer TFH cells.  
Reconstituted B6 and BAFF-/- chimeras were immunized with NP-14-KLH precipitated in 
alum.  (C and D)  At 7 days post-immunization, spleens were harvested and CD4+, 
CXCR5+, an PD-1+ T cells were enumerated by flow cytometry.* p < 0.05,    ** p < 0.01, 
unpaired t test 
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Fig. 2.13  DC-derived BAFF restores TFH population in immunized CD16-/- mice.
Fig. 2.13  DC-derived BAFF restores TFH population in CD16-/- mice.   BMDCs 
were prepared from B6 and BAFF Tg mice.  B6 or BAFF Tg BMDCs were 
subcutaneously injected into CD16-/- mice, immunized with NP-14-KLH.  Inguinal 
lymph nodes were harvested seven days post-immunization, and assessed for the 
presence of CD4+ TFH cells by flow cytometry.   * p < 0.05, n.s: not significant, 
unpaired t test 
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2.14 Immunized BAFF-/- chimeras also have reduced levels of Bcl-6 expression.
2.14 Immunized BAFF-/- chimeras also have reduced levels of Bcl-6.  Reconstituted 
B6 and BAFF-/- chimeras were immunized with NP-14-KLH precipitated in alum.  At 7 
days post-immunization, spleens were harvested and intracellular Bcl-6 expression 
was assessed by flow cytometry in CD4+ T cells (A.) and GC (CD19+, CD95+, GL-7+) 
B cells (B.)  n =4.  * p < 0.05, ** p < 0.01, n.s:  not significant, one sample t test 
 
B. 
 
A. 
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Fig. 2.15  DC-derived BAFF restores Bcl-6 expression in immunized CD16-/- mice.
Fig. 2.15  DC-derived BAFF restores Bcl-6 expression in CD16-/- mice.   BMDCs 
were prepared from B6 and BAFF Tg mice.  8 X 106 wild type or BAFF Tg BMDCs 
were subcutaneously injected into CD16-/- mice, immunized with NP-14-KLH.  Inguinal 
lymph nodes were harvested seven days post-immunization, and intracellular Bcl-6 
expression in CD4+ T cells (A.) and GC B cells (B.) was assessed by flow cytometry.  
n=5 *p <  0.05, **p < 0.01, one sample t test  
A. B. 
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CHAPTER 3 
 
BAFF is essential for memory B cell reactivation 
 
3.1 Introduction 
Antigen-specific recall responses initiated by memory B cells promote accelerated 
clonal expansion, rapid differentiation, and also give rise to high-affinity plasma cells as well 
as the replenishment of the memory B cell pool (1-3).   The cellular and molecular basis for 
the faster and more robust response after antigen re-exposure remains unclear.  Many studies 
have been aimed at understanding the intrinsic characteristics of memory B cells that enable 
robust secondary responses.  Studies have found that the class-switched, IgG B cell receptors 
(BCRs) of memory B cells have enhanced signal initiation and microclustering compared to 
the BCRs of naïve B cells (4). The cytoplasmic tails of the BCRs of memory B cells also 
contribute to the burst of clonal expansion associated with antigen re-encounter (5).  There is 
also evidence that there are significant changes in BCR signaling pathways of memory B 
cells.  CD22-mediated signaling inhibition is prevented in memory B cells, thus enhancing 
BCR activation. (6).  Increased affinity for antigen could also contribute to rapid reactivation 
of memory B cells and enhanced sensitivity to low doses of antigen that are otherwise unable 
to induce a primary immune response.   
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Much less is known about the extrinsic factors that promote the expansion of antigen-
experienced plasma and memory B cells during recall responses.  Circulating, high-affinity 
antibodies also contribute to memory B cell expansion, as rapid presentation of immune 
complexes to memory B cells is enhanced (1).  There is also some evidence that memory B 
cells require cognate interaction with antigen-specific T helper cells to initiate secondary 
immune responses (1, 7). When the initial priming antigen and antigen presented during 
recall responses are identical, memory TFH cells emerge and are reactivated preferentially 
over their naïve counterparts.  The organization and kinetics of this process remain poorly 
understood.  In addition, the specific role of TFH cells in enhancing secondary immune 
responses has not been well studied.   
There has also been recent evidence that memory B cells can re-initiate a GC reaction 
following antigen recall (8). The type of antigen appears to have an impact on the persistence 
of the primary-response GC, with particulate antigens (sRBCs) more likely than soluble 
antigens (NP-KLH), to sustain germinal centers (8). Whether the germinal centers observed 
during secondary responses are a continuation and re-expansion of a primary GC remains to 
be determined. More importantly, it remains to be seen whether these secondary germinal 
center structures support the replenishment of the memory B cell pool, the further 
diversification of affinity-matured BCRs, and the selection of B cell clones with higher 
affinities.  The role of additional extrinsic factors, including cytokine production, in 
promoting antigen recall responses also requires further investigation. IL-21 plays a role in 
the accumulation of memory B cells and plasma cells following secondary immunization (9); 
however, it is not the sole factor responsible for memory B cell reactivation.  Furthermore, 
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the mechanism by which IL-21 enhances memory B cell responses remains unclear; perhaps 
IL-21 synergizes with additional factors to promote memory B cell expansion. 
Although a role for BAFF in B cell survival and homeostasis is well defined, its 
impact on B cells during memory responses remains unclear.  Our studies reported herein 
demonstrate that during antigen recall responses, BAFF is essential for the expansion of 
memory B cells.  The reduction of serum BAFF levels by BR3-Fc treatment resulted in 
decreased secondary NP-specific antibody responses.  This deficit in secondary humoral 
responses was also associated with the failure of NP-specific memory B cells to expand into 
effector, antibody-secreting cells.  This defect in secondary immune responses was also 
associated with a reduction in germinal center B cells and TFH cells. 
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3.2 Materials and Methods 
Animals 
Animals were maintained in an accredited animal facility at University of North Carolina. 
C57BL/6 (B6) mice were bred in house and used at 8-12 weeks of age.  
Antibodies and Reagents  
Antibodies to CD19, CD4, GL-7, PD-1, and ICOS were purchased from Biolegend.  
Antibodies to murine IgG1, IgG2a, IgG2b, IgG3, and CXCR5 were purchased from BD 
Biosciences.  Streptavidin Alexa 488 and Streptavidin Alexa 647 were purchased from 
Invitrogen. Purified antibodies from the hybridomas H33L and B1-8 were obtained from Dr. 
Garnett Kelsoe of Duke University.  BR3-Fc and control antibody IgG-Fc were obtained 
from Dr. Robert Benschop of Eli Lilly.  NP-Osu was purchased from Biosearch 
Technologies, and KLH was purchased from Sigma Aldrich.  Alum was purchased from 
Pierce.   
NP-KLH immunization 
B6 mice (8-12 weeks of age) were immunized i.p. with 100 µg NP-14-KLH precipitated in 
alum for the induction of primary responses.  For secondary immunization, mice were 
boosted (i.v. injection) with 100 µg of soluble NP-14-KLH at least 30 days after the primary 
immunization. Antibody levels were measured 4, 7, and 14 days after boost to quantitate 
memory recall responses. 
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BR3-Fc Treatment 
Twenty-eight days following the initial NP14-KLH immunization, the mice were injected 
(i.v) with 5 mg/kg of either control IgG-Fc or BR3-Fc at bi-weekly intervals.  In vivo BAFF 
depletion was assessed by flow cytometry in the enumeration of CD19+ B cells. 
NP ELISA 
Sera were tested for IgG anti-NP antibodies by ELISA. Microtiter plates were coated with 5 
µg/mL NP13-conjugated BSA (Biosearch Technologies). Serially diluted serum samples were 
incubated overnight at 4oC. The anti-NP hybridoma, H33L was used as a standard for 
quantitation.  Anti-NP IgG levels were detected using an alkaline phosphatase-conjugated 
goat anti-mouse IgG antibody (1/1000 dilution) followed by phosphatase substrate (Sigma-
Aldrich).  Optical density (OD) values were converted to concentration based on standard 
curves, using a four-parameter logistic equation (Softmax Pro 3.1 software; Molecular 
Devices). 
NP ELISpot 
 Splenocytes from immunized mice were washed and transferred to plates coated with 10 
µg/mL NP13-conjugated BSA and incubated for 48 hrs (0.25 X 106 cells/well).  The ASCs 
were detected using biotinylated anti-IgM and IgG followed by streptavidin-horseradish 
peroxidase.  The plates were analyzed using an ImmunoSpot Analyzer and ImmunoSpot 
software package (Cellular Technology). 
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TFH Cell Enumeration 
B6 mice (8-10 weeks of age) were immunized and treated with BR3-Fc as described.  At day 
14 post-immunization, spleens were harvested, single cell suspensions were prepared, and 
CD4+, CXCR5+, PD-1+, and ICOS+ T cells were enumerated by flow cytometry.   
Statistical analysis 
The student’s t test was used to compare Ig secretion following the boost in IgG-Fc control-
treated and BR3-Fc-treated mice.  The unpaired t test was used to compare ELISpot results, 
GC B cell and TFH cell numbers in IgG-Fc and BR3-Fc treated mice.  Statistical analyses 
were performed with GraphPad Prism. 
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3.3 Results  
3.3.1 BAFF is required for memory B cell reactivation 
 Our studies thus far show that CD16-/- mice and BAFF-/- bone marrow chimeras fail 
to mount secondary immune responses, as indicated by reduced antibody levels following 
boost with antigen, as compared to immunized B6 mice.  This defect in secondary immunity 
has been attributed to a reduction in memory B cell formation during the primary immune 
response.  Alternatively, the reduced levels of anti-NP antibody during recall responses could 
result from the failure of the existing antigen specific memory B cells to expand and secrete 
antibody after secondary antigen exposure due to the lack of localized BAFF production.  To 
assess the role of BAFF in memory B cell reactivation, wild type B6 mice were immunized 
with the T-dependent antigen NP-KLH and subsequently dosed with a 5 mg/kg dose of BR3-
Fc to reduce serum BAFF levels.  BR3-Fc treatment was initiated at 28 days post-
immunization to allow for a normal primary immune response to NP-KLH immunization.  
By day 28 post-immunization, the primary response has contracted (10), and only the role of 
BAFF in memory B cell expansion and antigen recall was assessed.  Following the bi-weekly 
dosing of B6 mice with BR3-Fc, we found that the percentage of CD19+ B cells was 
decreased by 50%, indicating that the mature B cell compartment was sensitive to the 
reduction of serum BAFF levels (Figure 3.2). No significant changes in B cell numbers were 
found in IgG-Fc treated mice (Figure 3.2).   Following the final dose of BR3-Fc, the mice 
were boosted with soluble NP-KLH and antibody responses were assessed by ELISA. We 
found that BR3-Fc treated mice had 2-fold lower anti-NP IgG antibody responses when 
compared to the IgG-Fc-treated control mice at 14 days post-boost (Figure 3.3).  We also 
observed a slight, but not statistically significant, decrease in anti-NP IgM levels in the BR3-
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FC injected mice at 7 days post-boost (Figure 3.3).  In addition, the BR3-Fc treated mice 
displayed 50% fewer anti-NP IgG antibody secreting effector cells at 14 days post-boost, as 
indicated by an ELISpot assay (Figure 3.4).  Overall, these results suggest that BAFF is 
necessary for the expansion of memory B cells and robust humoral responses during re-
encounter with antigen. 
3.3.2 BR3-Fc treated mice have reduced germinal center B cells and TFH cells 
 Studies have shown that activated B cells can re-enter germinal center structures in 
secondary immune responses (8).  Thus, it is possible that the failure to secrete antibody 
during recall responses could result in the lack of germinal center re-formation or re-
utilization.  To assess germinal center B cell responses following antigen boosting, spleens of 
immunized, BR3-Fc treated mice were sectioned and analyzed by immunofluorescence for 
the presence of germinal centers.  We found that BR3-Fc treated mice did indeed show 
clustering of PNA+, B220+ B cells, indicative of germinal center structures (data not shown).  
However, in contrast to IgG-Fc treated control mice, BR3-Fc treated mice displayed germinal 
centers of a smaller size, most likely due to a reduction in the numbers of mature B cells 
(data not shown).  In addition, the absolute number of CD19+, CD95+, GL-7+ germinal center 
B cells was reduced by approximate 55% at 14 days post-boost in the BR3-Fc treated mice, 
compared to control mice, as indicated by flow cytometric analysis (Figure 3.5).   Because 
germinal center formation requires proper TFH cell function and maintenance, we assessed 
the numbers of CXCR5+,  PD-1-/-, CD4+ T cells within the spleens of immunized B6 mice 14 
days post boost. Corresponding with a change in germinal centers, we also found that the 
reduction in BAFF serum levels resulted in a 40% reduction in CXCR5+, CD4+ B cells 
(Figure 3.6).  No changes in PD-1 or ICOS expression were observed.  Taken together, these 
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data suggest that the presence of BAFF in secondary immune responses influences germinal 
center responses and CXCR5 upregulation of CD4+ T cells during secondary immune 
responses. 
Our results demonstrate that BAFF is a required factor for memory B cell reactivation 
during secondary immune responses.  This suggests that BAFF is necessary for plasma cell 
differentiation from activated memory B cells after re-encounter with antigen.  In addition to 
fewer anti-NP ASCs following the boost in BR3-Fc injected mice, we also found that there 
were fewer GC B cells and TFH cells present in the spleens of BAFF-depleted mice.  Overall, 
these data suggest that BAFF has a novel role in productive B and T cell responses upon 
antigen recall responses. 
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3.4 Discussion 
During the secondary immune response, re-encounter with antigen results in the 
expansion of memory B cells into effector antibody-secreting cells and the generation of 
additional memory B cells. Our studies indicate that BAFF has many regulatory roles in 
adaptive immunity, including modulating the expansion of B cells during secondary immune 
responses.  This expansion results in a robust antibody response that protects the host from 
secondary infection by the pathogen.  Our data indicate that BAFF is critical for memory B 
cell expansion and antibody responses following re-encounter with antigen.  As a result of in 
vivo BAFF reduction, IgG antibody responses are significantly attenuated following the boost 
with NP-KLH. 
The exact mechanism by which BAFF regulates memory B cell reactivation and 
secondary immunity remains unclear.  Because there is some literature to suggest that naïve 
B cells can participate in secondary immune responses (11), it is possible that the depletion 
of naïve B cells from the BR3-Fc treatment is indirectly responsible for the lack of secondary 
responses. Alternatively, BR3-Fc treatment could directly inhibit the BCR activation of 
memory B cells once they have encountered antigen. There is also some evidence of 
signaling cross-talk between the BAFF receptor and the BCR and of BAFF enhancing BCR 
signaling (12).  Thus, loss of BAFF signaling may also interfere with the threshold of B cell 
receptor activation and memory B cell function.  
It has also been proposed that germinal centers contribute to secondary immune 
responses (8).  Studies have also shown germinal centers can be reutilized by newly activated 
B cells (13).  Our studies would suggest that BAFF inhibition by BR3-Fc treatment might 
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disrupt the seeding of secondary germinal centers and TFH cell function during secondary 
immune responses, thereby preventing the rapid antibody response that is required to 
neutralize the intruding pathogen.  Recent studies have shown that memory TFH cells reside 
in close proximity to IgG memory B cells, which surround contracted germinal centers in the 
spleen (7).  These studies propose that the close proximity of memory B and TFH cells 
contribute to the rapid kinetics of secondary immune responses.  It is also possible that 
additional factors such as BAFF are required for the localization of memory B cells and TFH 
cells during antigen re-encounter.  Our studies show that BAFF is required for the 
upregulation of the chemokine receptor CXCR5 on CD4+ T helper cells.  Thus, BAFF may 
promote the homing of memory TFH cells into the B cell follicle, which allows for successful 
memory B cell activation.  Because B cells are required for TFH cell maintenance (14), the 
lack of CXCR5-expressing helper T cells could also be the product of partial B cell depletion 
resulting from BR3-Fc treatment.  Future studies are required to further delineate the direct 
role of BAFF in TFH cell function during secondary immune responses.   
Our studies show that BR3-Fc treatment results in a reduction in total TFH cell 
numbers during antigen recall.  This would suggest that B cell depletion by in vivo BAFF 
neutralization also directly impacts T cell maintenance and the generation of T cell memory.  
Perhaps the reduced secondary responses following BR3-Fc treatment is also a result in the 
loss of function of memory T cells.  Numerous reports have indicated that B cells can 
regulate CD4+ memory T cell responses.  In one study, using infection with 
Heligmosomoides polygyrus as a model, B cells were required to maintain and reactivate 
antigen-specific memory T helper cells (15).   Similar results were found in a model of 
LCMV infection where LCMV-specific memory CD4+ T cells failed to survive in B cell-
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deficient mice (16).  Combined, these studies indicate that B cells have a role in establishing 
and maintaining antigen-specific memory T cell populations.  Thus, failure to mount robust 
antibody responses could not only reflect the inability to activate memory B cells in the 
absence of BAFF, but also failure to activate antigen-specific memory T cells as a result of 
partial B cell depletion. 
 The role of BAFF in memory B cell activation has vast implications in the regulation 
of memory to self-antigens in the setting of autoimmune disease.  Our studies show that anti-
BAFF immunotherapy has the potential to prevent autoreactive memory B cell activation in 
response to recognition of self-antigens.  BAFF is known to provide a survival mechanism 
for autoreactive B cells, and BAFF over-expression has been linked to autoimmunity (17).   
Specifically, BAFF transgenic mice develop lupus-like disease as they age (18). In addition, 
high serum levels of BAFF have been found in a select group of SLE patients (17, 19).  This 
clearly demonstrates a pathogenic role for BAFF initiating and sustaining autoimmune 
diseases. Our data reported herein demonstrate that the reduction of serum BAFF levels in 
vivo by BR3-Fc treatment results in the failure to reactivate memory B cells during secondary 
immune responses.  Although previous reports have shown that memory B cell survival is 
independent of BAFF (20, 21), previous studies have not addressed the role of BAFF during 
antigen recall.  Our data indicate that BAFF is indispensable in the activation of memory B 
cells during re-exposure to antigen in secondary immune responses.  Thus, anti-BAFF 
therapies to treat autoimmune disease may contribute to the amelioration of disease by 
preventing memory B cell responses to self-antigen.   
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 Fig. 3. 1  Reduction of serum BAFF levels by BR3-Fc treatment in B6 mice. 
   
 
 
  
 
 
 
 
 
 
 
Fig. 3. 2  Treatment with BR3-Fc results in reduced numbers of CD19+ B cells in B6 mice. 
Fig. 3. 1  Reduction of serum BAFF levels by BR3-Fc treatment in B6 mice. 8-12 week 
old female B6 mice were immunized with  100 µg NP-14-KLH (i.p.).  At 28 days post-
immunization, mice were treated with 5 mg/kg of the control antibody, IgG-Fc, or the BAFF 
depleting reagent, BR3-Fc.  Mice were boosted one week after the 2nd dose of BR3-Fc.  Mice 
were bled 4, 7, and 14 days following boost with NP-KLH.  Serum anti-NP levels were 
assessed by ELISA. 
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Fig. 3. 2  Treatment with BR3-Fc results in fewer CD19+ B cells in B6 mice.   8-12 
week old female B6 mice were immunized with 100 µg NP-14-KLH (i.p.).  At 28 days 
post-immunization, mice were treated with 5 mg/kg of the control antibody, IgG-Fc, or 
the BAFF depleting reagent, BR3-Fc.  CD19+ B cells were enumerated by flow 
cytometry. **p < 0.01, n.s: not significant, unpaired t test 
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Fig. 3.3 BAFF is required for memory B cell reactivation in secondary immune responses.
 
Fig. 3.3 BAFF is required for memory B cell reactivation. 8-12 week old B6 mice were 
immunized with 100 µg NP-14 KLH (i.p.).  28 days post-immunization mice were dosed 
with 5 mg/kg IgG-Fc or BR3-Fc at bi-weekly intervals. Following BR3-Fc treatment, both 
cohorts of mice were boosted with soluble NP-14-KLH.  Serum IgM (A.) and IgG (B.) 
anti-NP levels were measure by ELISA 4, 7, and 14 days post-boost.  n=8 mice per 
treatment group. *p < 0.05, Student’s t test 
A. B. 
* 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Fig. 3.4 BAFF is required for memory B cell expansion in response to re-encounter with 
antigen.
Fig. 3.4 BAFF is required for memory B cell expansion.   8-12 week old B6 mice 
were immunized with 100 µg NP-14 KLH (i.p.).  28 days post-immunization mice were 
dosed with 5 mg/kg IgG-Fc or BR3-Fc at bi-weekly intervals. Following BR3-Fc 
treatment, both cohorts of mice were boosted with soluble NP-14-KLH.  Anti-NP ASCs 
were enumerated at day 28 post-immunization and 14 days, post-boost by ELISpot. *p < 
0.05, unpaired t test 
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Fig. 3. 5  BR3-Fc treated mice have fewer GC cells, 14 days post-boost.
Fig. 3. 5  BR3-Fc treated mice have fewer GC cells, 14 days post-boost.  8-12 week 
old B6 mice were immunized with 100 µg NP-14-KLH (I.p.).  At 28 days post-
immunization, the mice were treated with 5 mg/kg of the control antibody, IgG-Fc, or 
the BAFF depleting reagent, BR3-Fc.  Following treatment with IgG-Fc or BR3-Fc, 
mice were boosted with 100 µg soluble NP-14-KLH.  CD19+, GL-7+, CD95+ GC B 
cells were enumerated by flow cytometry 14 days post-boost.  *p < 0.05, **p ≤ 0.01, 
unpaired t test 
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Fig. 3. 6  BR3-Fc treated mice have fewer CD4+, CXCR5+ TFH cells 14 days post-boost.
 
Fig. 3. 6  BR3-Fc treated mice have fewer cells 14 days post-boost.  8-12 week old B6 
mice were immunized with  100 µg NP-14-KLH (I.p.).  At 28 days post-immunization, mice 
were treated with 5 mg/kg of the control antibody, IgG-Fc, or the BAFF depleting reagent, 
BR3-Fc.  Following treatment with IgG-Fc or BR3-Fc, mice were boosted with 100 µg 
soluble NP-14-KLH.  14 days following the boost, CD4+, CXCR5+ T follicular helper cells 
were enumerated by flow cytometry.  *p < 0.05, **p ≤ 0.01, unpaired t test 
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CHAPTER 4 
 
B cells secrete cytokines to regulate antigen-induced Ig secretion 
 
 4.1  Introduction 
 The production of high-affinity, antigen-specific antibodies during the adaptive 
immune response is critical in the host’s survival during infection.  The proper contraction of 
antibody production by activated B cells is also important in preventing inappropriate 
immune responses, which could lead to excess inflammation and, in extreme instances, 
malignancies and autoimmunity.  Several regulatory mechanisms have been described that 
contribute to the regulation of B cell activation thresholds, including immune complexes 
binding FcγRIIb  on the B cell surface.  FcγRIIb , along with other inhibitory receptors such 
as PD-1, CD-5, and CD22, belong to the family of ITIM-containing immune inhibitory 
receptors.  Fc receptor ligation on the surface of B cells results in SHIP phosphatase 
recruitment and attenuated BCR signaling (2, 3).  Studies in FcγRIIb -/- mice have 
demonstrated its role in enhancing humoral immunity.  However, the absence of FcγRIIb  
does not result in uncontrolled antibody production, indicating the presence of additional 
regulatory mechanisms.  Other mechanisms of immune regulation include the generation of 
regulatory T and B cells, whose main function is to secrete regulatory cytokines that dampen 
the immune response.  There is a large body of evidence demonstrating the role of regulatory 
T cells and their production of TGF-β in modulating T helper cell responses, and in some 
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cases, the function of activated B cells (4-6). Although they are mostly characterized by their 
production of immunoglobulins and their role in secondary antigen presentation, B cells are 
also capable of additional immunoregulatory functions. Regulatory IL-10-producing B cells 
can suppress CD4+ T cell responses and can prevent the induction of autoimmune disease in 
several mouse models (7).  Although there is emerging evidence of a key role for regulatory 
B cells in regulating T cell responses and maintaining tolerance, little is known about the role 
of antigen-stimulated B cells in actively regulating effector function of newly emerging naive 
B cells and antibody secretion via autocrine mechanisms.  It also remains unclear whether B 
cells secrete other regulatory cytokines, in addition to IL-10. 
Our data reported herein support a model in which antigen-stimulated B cells, 
independent of Fc receptor ligation, secrete the soluble regulatory factors TGF-β and CD40L, 
which negatively impact effector functions of newly stimulated B cells in vitro.  We propose 
that the production of regulatory cytokines by B cells functions as a feedback mechanism that 
limits Ig production following a productive immune response.  In addition, our studies 
suggest the production of TGF-β and CD40L by B cells also plays a role in the maintenance 
of tolerance to self-antigens, as B cells from lupus-prone mice fail to regulate Ig secretion.  
Overall, our studies demonstrate that in addition to immunoglobulin production and antigen 
presentation, B cells have an important role in regulating antigen-induced B cell responses. 
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4.2  Materials and Methods 
Animals 
Animals were maintained in an accredited animal facility at University of North Carolina. 
C57BL/6 (B6), FcγRIIb -/-, B6.lpr, and MRL/lpr mice were bred in house and used at 10-12 
weeks of age.  OTII TCR transgenic mice and B6 Mertkd were obtained from Jenny Ting and 
Glenn Matsushima, from the University of North Carolina.  
B and T cell purification 
Splenic B cells were isolated from B6, FcγRIIb -/-, MRL/lpr, Mertkd, and B6.lpr mice by 
negative selection (StemCell Technologies). B cells were 95-99% pure, as determined by 
flow cytometry (with fewer than 5% DCs and MFs).  In some experiments, marginal zone 
(MZ) B cells were depleted by the addition of biotinylated anti-CD9.  Splenic T cells were 
isolated from OTII TCR transgenic mice by negative selection (StemCell Technologies).  T 
cells were 90-99% pure, as determined by flow cytometry.   
Antibodies and Reagents 
Recombinant murine IL-4 and IL-5 were purchased from Peprotech. Monoclonal antibodies 
54.1 (3-83 idiotype), Y-12 (anti-Sm), and 33-60 and B7.6 (anti-mu) were purified from 
hybridoma culture supernatants.  Streptavidin microbeads were purchased from Miltenyi. 
Whole ovalbumin protein was purchased from Sigma Aldrich.  Neutralizing antibodies (anti-
TGF-β  and anti-CD40L) were purchased from R&D Systems. 
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Preparation of B cell conditioned media (CM) 
2 X 105 purified B cells were stimulated with 30 µg/mL anti-mu (B7.6 complexed to 
streptavidin microbeads), rIL-4 and rIL-5 (10 ng/mL). After seven days of culture, 
supernatants were harvested, and stored at -20oC for future use. 
B6 B cell and OTII T cell co-culture 
2 X 105 purified B6 B cells were co-cultured with 2 X 105 T cells purified from OTII TCR 
transgenic mice.  Cells were cultured for 7 days in the presence of 100 µg ovalbumin.  
Supernatants were harvested on day 7, and IgM was measured by ELISA, or stored at -20oC 
for future use.   
Total IgM ELISAs 
IgM levels from B6 mice were detected using anti-mouse IgM (33-60) and biotin-labeled 
anti-mouse IgM (B7.6). 
Neutralization of B cell CM 
B cell CM were pre-incubated with anti-TGF-β, anti-CD40L , or isotype control antibodies 
(54.1 and Y-12) for one hour prior to addition to purified B cells and cultured with anti-mu 
stimulated B cells for seven days. Supernatants were harvested, and secreted IgM was 
quantitated using ELISA. 
Statistics 
The one sample t test was used to compare secreted IgM levels in anti-mu stimulated controls 
and treatment groups.  Statistical analyses were performed using Graph Pad Prism. 
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4. 3 Results 
4.3.1 Antigen-stimulated B cells secrete repressive factors 
B cells primarily function in antigen-specific adaptive immune responses by secreting 
high-affinity antibodies to neutralize invading pathogens.  Few studies have addressed the 
role of B cells in directly regulating B cell effector responses, including the production of 
immunoglobulin.  It is unclear whether B cells produce factors during antigen stimulation 
that negatively regulate B cell responses through a feedback mechanism.  To assess whether 
B cells possess the ability to regulate Ig secretion through an autocrine mechanism, wild type 
B6 B cells were stimulated with anti-mu, rIL-4, and rIL-5 for seven days to mimic a T-
dependent, adaptive immune response.  After 7 days, supernatants from the stimulated B 
cells (B cell conditioned media (CM)) were harvested and tested for repressive capabilities.  
Subsequently, additional B6 B cells were purified, stimulated with anti-mu, and cultured with 
the B cell CM.  We found that anti-mu stimulated B cells cultured with B cell CM showed a 
95% reduction in Ig secretion compared to the anti-mu stimulated control B cells (Figure 
4.1).  We also found that while Ig secretion was significantly inhibited by culture with B cell 
CM, cell proliferation and viability remained unaffected (data not shown). 
4.3.2 The production of regulatory factors by activated B cells is independent of Fc 
receptor ligation 
Because B cells express the inhibitory Fc receptor FcγRIIb, which negatively 
regulates B cell activation, it is possible that the B cell CM inhibits Ig production through an 
Fc-dependent mechanism, involving immune complex binding by FcγRIIb .  To test this, B 
cells were purified from FcγRIIb -/- mice, stimulated with anti-mu and rIL-4/5, and cultured 
with B cell CM from B6 mice.  The repressive ability of the CM was independent of Fc 
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receptor ligation since Ig secretion of B cells from FcγRIIb deficient mice was also inhibited 
by the B cell CM (Figure 4.1).  Furthermore, CM prepared from wild type B cells using anti-
mu F(ab)2  also inhibited Ig production (Figure 4.1), indicating that the presence of the Fc 
portion of antibody is not required for B cell-mediated repression of Ig secretion.    
4.3.3  Ovalbumin-stimulated B cells secrete factors that negatively impact Ig secretion 
To confirm that the mechanism by which B cells auto-regulate Ig production is not 
unique to anti-mu stimulation, an in vitro culture system was designed to stimulate B cells 
using bona fide antigen and T cell help.  Purified wild type B6 B cells were stimulated with 
ovalbumin protein in the presence of OTII T cells, which express an ovalbumin-specific T 
cell receptor (TCR).  In the presence of ovalbumin and antigen-specific T cells, B6 B cells 
proliferated (Figure 4.2) and secreted Ig, indicating a productive immune response to 
ovalbumin stimulation.  Conditioned media from these stimulated B cells was harvested and 
tested for its repressive abilities (OVA B cell CM).  Freshly isolated B6 B cells were 
ovalbumin-stimulated and cultured with the OVA B cell CM.  We found that Ig secretion 
was inhibited by 60% (Figure 4.2), indicating that these repressive effects of the B cell CM 
are not unique to anti-mu B cell stimulation, but also impact B cells stimulated with bona 
fide antigen. 
4.3.4 CD9 expressing B cells secrete soluble factors that inhibit Ig secretion 
During the process of B cell development in bone marrow, naive B cells differentiate 
and migrate to different microenvironments, so that peripheral lymphoid tissues contain 
mature B cell subsets with varying phenotypes and functions (8).  Although the majority of B 
cells in the spleen are located in the follicular (FO) area, B cells of slightly larger size are 
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located in the marginal zone and are more readily activated (9, 10). Because B cells with an 
origin similar to the marginal zone have been ascribed regulatory functions (11), we wanted 
to identify the B cell subset secreting the regulatory factors.  Studies have shown that 
regulatory B cells play a major role in maintaining immune tolerance and that the function of 
these B cells is dysregulated in SLE patients (12). To identify the B cell subset, we purified B 
cells from B6 mice and subsequently depleted the marginal zone subset using an anti-CD9 
antibody.  Marginal zone depletion was confirmed by flow cytometry, as demonstrated by 
the near absence of CD21high, CD23low, CD19+ B cells (13).  The remaining B cells were then 
anti-mu stimulated and CM was harvested after seven days.  We found that B cells stimulated 
with CM from marginal zone-depleted B cells failed to inhibit Ig secretion (Figure 4.3), 
demonstrating that the source of the repressive factors was the marginal zone subset.  
Because B cells of the B-1 subset and some plasma cells also express CD9, we cannot rule 
out the contribution of these B cell subsets in regulation Ig secretion (13). 
4.3.5 Ag-stimulated B cells secrete TGF-β and CD40L, which regulate Ig production 
 We have now identified a novel mechanism by which B cells secrete soluble factors 
that regulate Ig production, independent of Fc receptor ligation. We next wanted to identify 
the soluble factors secreted by B cells upon stimulation.  We began by neutralizing the CM 
with a panel of antibodies against cytokines that are secreted by B cells and are known to 
have regulatory roles in the immune response.  Ig secretion by stimulated B cells cultured 
with CM neutralized with either anti-TGF-β or anti-CD40L alone remained inhibited (Figure 
4.4 A).  We found that when the B cell CM was neutralized with both anti-TGF-β and anti-
CD40L, Ig secretion by the B cells was fully restored to levels similarly observed in anti-mu 
stimulated controls (Figure 4.4 A). These results were not due to non-specific antibody 
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binding because restoration of Ig secretion was not observed when CM treated with isotype 
controls.  These results indicate that B cells secrete TGF-β  and CD40L, which limit Ig 
production by other antigen-stimulated B cells.  Furthermore, when B cells were cultured 
with both recombinant TGF-β and CD40L combined, Ig secretion was reduced to 90% of the 
anti-mu stimulated controls (Figure 4.4), while proliferation remained unaffected (data not 
shown). 
4.3.6 B cells from lupus-prone mice fail to repress Ag-induced Ig secretion 
Our studies suggest that B cells secrete TGF-β  and CD40L, which negatively 
regulate Ig secretion by other antigen-stimulated B cells. It is also possible that these 
regulatory factors may play a role in maintaining tolerance to self-antigen and preventing 
activation of self-reactive B cells, as previous studies in our lab have shown that CD40L 
prevents TLR-activation of Sm-specific B cells (14).  Furthermore, DCs and MFs from 
lupus-prone mice fail to secrete regulatory factors in response to LPS stimulation (15).  If 
TGF-β and CD40L play a significant role in maintaining tolerance, one would predict that B 
cells from autoimmune-prone mouse models, in which tolerance has been breached, would 
show decreased production of these regulatory cytokines.  To test whether these factors have 
a role in immune tolerance to self-antigen, B cell CM were prepared from the lupus-prone 
mouse model MRL/lpr and from mouse models with known clearance defects and an 
increased propensity for autoimmunity (B6.lpr and Mertkd).  We found that compared to CM 
from wild-type mice, B cell CM from MRL/lpr, Mertkd, and B6.lpr mice failed to inhibit IgM 
production by anti-mu stimulated B6 B cells (Figure 4.5).  B cells cultured with these CM 
secreted levels of IgM that were comparable to anti-mu stimulated controls.  These data 
suggest that B cells from lupus-prone mice fail to secrete the regulatory products.  Failure to 
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maintain tolerance to self in these lupus-prone mouse models could be partially attributed to 
the lack of TGF-β  and CD40L production by antigen stimulated B cells. 
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4.4 Discussion 
 Robust B cell activation is critical in providing the host with protective humoral 
immunity against invading pathogens.  Tightly regulated B cell activation and subsequent 
antibody production allows for the effective neutralization of foreign antigen, while 
maintaining unresponsiveness to self-antigens.  Mechanisms to induce proper contraction of 
the immune response must also exist to prevent uncontrolled antibody responses and 
inflammation. Dysregulation of B cell responses can lead to several pathological conditions, 
including lymphoid cancers, autoimmunity, and immunodeficiency.  Historically, the 
activation of ITIM-containing inhibitory cell surface receptors, including FcγRIIb , has been 
recognized as an essential mechanism in regulating BCR signaling thresholds and B cell 
proliferation and Ig secretion (16).  However, additional mechanisms must exist, as FcγRIIb-/- 
mice can still attenuate BCR-derived antibody responses (1).  In summary, we have found 
that antigen-stimulated B cells, predominantly of the marginal zone subset, produce the 
regulatory factors TGF-β and CD40L, which negatively impact Ig secretion in vitro.  These 
data suggest that B cells themselves have an active role in regulating BCR-derived immune 
responses. Our data also highlight the importance of these regulatory cytokines produced by 
B cells in models of autoimmunity because B cells from lupus prone mice fail to secrete 
factors that regulation Ig secretion. 
 In addition to immunoglobulin production and providing co-stimulation to T cells, it 
has been well documented that B cells can also secrete cytokines and chemokines in response 
to antigen and other stimuli (17, 18).  Although it has been known for decades that B cells 
can secrete cytokines, the idea that B cell-derived cytokines are involved in regulating 
various components of the adaptive immune response is relatively new. The role of TGF-β  
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and CD40L production by marginal zone B cells in regulating adaptive immune responses in 
vivo has yet to be determined. Marginal zone B cells are strategically located in the periphery 
of the B cell follicle and are the first cells to encounter antigen from the bloodstream (19).  
As a result of their location, marginal zone B cells are more readily activated than follicular 
B cells and do not require T cell help (8, 19). MZ B cells preferentially secrete antibodies of 
the IgM and IgG3 isotypes, while follicular B cells preferentially secrete IgG1 or other Ig 
isotypes after stimulation, reflecting the role of MZ B cells in the primary T-independent 
response (19). Because our studies show that the CD9+ marginal zone B cells are the 
predominant producers of TGF-β and CD40L, it is possible that the primary function of B 
cell-derived TGF-β and CD40L in vivo is to modulate T-independent, extra-follicular 
antibody responses. Conditional knockout of TGF-β signaling in B cells results in 
exaggerated IgG3 responses, which is indicative of its role in T-independent B cell responses 
(20-22). Additional studies in our lab show that mice containing a conditional knockout of 
the TGF-β receptor on B cells have an expanded population of CD138+ pre-plasma cells at 3 
days post-immunization, thus supporting the role of TGF-β  in regulating the early extra-
follicular events in the adaptive immune response.  
The role of CD40L in regulating B cell responses and in the maintenance of immune 
tolerance also requires further investigation.  Several studies have demonstrated that CD40 
signaling by CD40L-expressing T cells promotes germinal center formation, isotype 
switching, affinity maturation, and the formation of long-lived plasma cells and B cell 
memory (23, 24).  The role of CD40-CD40L ligand interactions in inducing T-dependent 
immunity is well established; however, CD40 can also have an opposing function in 
regulating B cell responses.  Studies have shown that excessive signaling by CD40 can 
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impede the ability of B cells to differentiate to long-lived plasma cells (25).  Similarly, 
enhanced CD40 signaling attenuates long-lived immunity by inducing antigen-specific B 
cells to differentiate to short-lived plasma cells at the expense of germinal center formation 
and induction of B cell memory (26).  Studies have also shown that the administration of a 
CD40 agonist along with a T-dependent antigen ablates long-lived humoral immunity in 
favor of short-lived extra-follicular plasma cells (23, 26). Thus, enhanced CD40 signaling 
may also impact extra-follicular B cell responses, similar to TGF-β. 
Because B cell CM from lupus-prone mice fail to inhibit Ig secretion in vitro, TGF-β 
and CD40L also contribute to the maintenance of immune tolerance by preventing 
autoantibody production.  Our lab has previously demonstrated a role for CD40L in 
maintaining immune tolerance by preventing polyclonal activation of autoreactive B cells 
during TLR-induced innate immune responses (14).  Our current studies reported herein also 
implicate CD40L in an additional role of regulating BCR-derived immune responses to self-
antigen.  The role of TGF-β preventing autoimmunity has been highlighted in several studies 
using TGF-β  mice, which succumb to severe systemic autoimmune disease shortly after birth 
(27).  In several other mouse models of autoimmunity, autoantibody production originates 
from B cells that reside outside of the follicle.  In MRL/lpr mice, for example, anti-DNA 
antibody production occurs in extrafollicular sites (28-30). Furthermore, AM14 rheumatoid 
factor-positive B cells on the MRL/lpr background can be activated by self-antigen, 
independently of T cell help and outside of germinal centers (31).  Because our in vitro 
studies suggest that lupus-prone mice fail to secrete repressive factors, one should consider 
that the inappropriate extrafollicular antibody responses observed in lpr deficient (MRL/lpr 
and B6.lpr) mice are a result of the failure to secrete repressive factors. 
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Further studies are required to link increased apoptotic burden resulting from the lack 
of Fas(lpr) or Mer expression to decreased production of regulatory factors by activated B 
cells, as indicated from our studies in Mertkd and B6.lpr mice.  There is a demonstrated 
relationship between failure to clear apoptotic debris and the development of autoimmunity 
in humans (32).  It is also believed that the increased availability of apoptotic cells caused by 
Mer and lpr mutations in mice could contribute to the induction of autoreactive B cell 
responses (33, 34).  It has been demonstrated that similar to defective Mer function (35), lpr 
mutations induce the activation of autoreactive marginal zone and peritoneal B-1 B cells by 
an antigen-specific mechanism (36). The similar outcomes of Mer and Fas (lpr) defects could 
be explained by the observations that both proteins have roles in apoptotic cell clearance 
(36). The increased activation of MZ B cells and the B1-subset in Mertkd and B6.lpr mice 
could be attributed to both the increased apoptotic burden and a subsequent lack of TGF-β 
production by marginal zone B cells.  Perhaps the increased apoptotic burden triggers 
production of TGF-β  by marginal zone B cells.  If TGF-β and CD40L do indeed negatively 
regulate extrafollicular IgM responses by marginal zone B cells, the lack of TGF-β 
production will lead to enhanced T-independent extrafollicular antibody responses that 
should promote non-pathologic clearance of the burden of apoptotic debris.  Additional 
studies are required to further define the link between apoptotic clearance and the secretion 
of regulatory factors by B cells.  
TGF-β is a well-known immunosuppressive cytokine, mainly produced by Foxp3+ T 
regulatory cells and is critical in limiting pro-inflammatory responses (4, 37). Our studies 
identify an additional source of TGF-β, and highlight a novel role for B cells in regulating 
BCR-derived humoral immune responses.   It is not surprising that B cells are able to 
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regulate humoral immune responses by an autocrine mechanism involving TGF-β because 
members of the TGF-β  family of proteins usually act in an autocrine or paracrine manner 
because the biological half-life of TGF-β  is very short (38).  Thus, the close proximity of 
activated TGF-β -secreting B cells within extrafollicular sites to newly emerging, naïve B 
cells is critical in maintaining tolerance and preventing unnecessary activation of additional 
B cells. There is increasing evidence to suggest that cytokines produced by B cells are also 
involved in mediating T cell responses.  One group has shown that Foxp3-expressing T 
regulatory cells proliferate in response to co-culture with resting B cells (39).  Thus, B cells 
may provide an additional source of TGF-β, which is likely to promote regulatory T cell 
expansion. Additional studies have also reported that B cell co-culture can induce anergy in 
both CD4+ and CD8+ T cells (40, 41).  Perhaps TGF-β derived from B cells has multiple 
functions in maintaining immune tolerance: first, to limit Ig production during extrafollicular 
responses; second, to suppress effector T cell function by inducing anergy; third, by 
enhancing the development and maintenance of regulatory T cells.  Overall, our studies 
highlight the importance of B cell derived cytokines in regulating B cell effector function in 
vitro.  Future studies are aimed at addressing the role of TGF-β and CD40L in regulating 
various elements of adaptive immunity in vivo, particularly extrafollicular responses. 
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4.1  Repression of Ig by B6 B cell CM is independent of CD32.
4.1  Repression of Ig by B6 B cell CM is independent of CD32.  B cells were purified 
from B6 and CD32-/- mice and stimulated with anti-mu (in addition to rIL-4 and rIL-5).  
B cells were also cultured with CM from B cells stimulated with either anti-mu with 
intact Fc, or anti-mu F(ab)2.  IgM secretion was measured by ELISA.  anti-mu 
stimulated controls secreted 15-31 µg/mL IgM.  n=4 * p< 0.05, one sample t test 
______ * 
____ * 
______ * 
____ * 
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4.2  OVA-stimulated B6 B cells also secrete factors, which repress Ig secretion.
4.2  OVA-stimulated B6 B cells also secrete inhibitory factors.  Purified B6 B cells were 
antigen stimulated with 100 µg/mL ovalbumin in the presence of OTII TCR Tg T cells.  CM 
from these B cells were harvested and cultured with freshly isolated B6 B cells, stimulated 
with ovalbumin (in the presence of OTII T cells.  Ovalbumin-stimulated B cells secreted an 
average of 1.2-2 µg/mL of IgM.  n=3 * p< 0.05, one sample t test 
_____ *  
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4.3  MZ B cells secrete factors that inhibit Ig secretion.
4.3  MZ B cells secrete factors that inhibit Ig secretion.  Splenocytes from B6 mice 
were depleted of marginal zone B cells by the addition of anti-CD9.  Purified, 
marginal zone depleted B cells were stimulated with anti-mu, rIL-4 and rIL-5. CM 
were harvested seven days after culture.  n=3  *p<0.05, n.s:  not significant, one 
sample t test 
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4.4  Ag-stimulated B cells secrete TGF-β and CD40L, which repress Ig secretion.
4.4  Ag-stimulated B cells secrete TGF-β  and CD40L (A).  B6 B cell CM were 
neutralized with 10 µg/mL of anti-CD40L and anti-TGF-β for 1 hour at room 
temperature. Neutralized supernatants were added to freshly isolated B6 B cells, and 
cultured for 7 days, with additional anti-mu, rIL-4 and rIL-5. n=4.  (B) B6 B cells were 
cultured with rCD40L (200 ng/mL) and/or rTGF-β (100 pg/mL) for 7 days with anti-
mu, rIL-4, and rIL-5. Total IgM secretion was measured by ELISA. anti-mu stimulated 
controls secreted 15-31 µg/mL IgM. n=4 *p<0.05, **p  < 0.01, n.s: not significant, one 
sample t test 
A.  B. 
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4.5.  B cells from lupus-prone mice fail to secrete factors that repress Ig secretion.
4.5.  B cells from lupus-prone mice fail to secrete repressive factors.  B cells 
were purified from either B6, MRL/lpr, Mertkd, or B6.lpr mice and stimulated with 
anti- mu, rIL-4, and   rIL-5 for 7 days.  B6 CM were harvested and cultured with B6 
B cells, in the presence of additional anti-mu, rIL-4 and rIL-5.  n=4.  ** p < 0.01, 
n.s:  not significant, one sample t test 
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CHAPTER 5 
 
Final Discussion 
 
5.1 Summary model 
Memory B cells and long-lived plasma cells generated from germinal centers provide 
durable protection from infectious disease and are essential for the maintenance of human 
health.  Plasma cells that develop in response to infection or vaccination secrete high levels 
of protective, high-affinity immunoglobulin (Ig) that persist for decades.  Upon re-encounter 
with pathogen, memory B cells quickly respond and differentiate into plasma cells, which 
enhance the pre-existing titers of antigen-specific antibody.  Although critical for host 
survival, the factors that govern these processes are not completely understood.  It is 
important to understand how germinal center initiation and the differentiation of memory B 
cells and plasma cells are regulated, as dysregulation at any step in B cell activation can be 
detrimental to the health of the host. 
 Using both in vitro and in vivo models, we have now identified novel mechanisms 
that regulate B cells during T-dependent immune responses.  We have found that dendritic 
cells sense the products of a productive immune response in the form of immune complexes 
(IC) and upon IC binding by Fc receptors, will secrete factors that influence critical events 
through the low-affinity IgG Fc receptor, CD16, and are induced to secrete the cytokine 
BAFF.  Our studies show that DC-derived BAFF is required for Bcl-6 expression within the 
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germinal center, which is essential for TFH cell maintenance and for the proper seeding and of 
the adaptive immune response.   Specifically, dendritic cells can bind IgG1-containing ICs 
initiation of the germinal center reaction. Our results from in vitro experiments indicate that 
the production of BAFF by DCs negatively regulates Ig production.  This result may seem 
paradoxical at first, given that BAFF is known to promote B cell responses.  We propose that 
BAFF serves to shut off plasma cell programming, by downregulating key transcription 
factors (XBP-1 and IRF-4), while promoting the formation of non Ig-secreting memory B 
cells.  We have also identified roles for BAFF in the reactivation of memory B cells during 
secondary immune responses.  Overall, our studies indicate that BAFF is not only essential 
for B cell survival and homeostasis (1), but it is also critical for key events during adaptive 
immunity, including memory B cell responses. 
5.2 The role of additional Fc receptors in mediating adaptive immune responses  
 Our current studies highlight CD16 activation and BAFF production by DCs in 
regulating germinal center responses and memory B cell formation in response to 
immunization with the soluble protein antigen NP-KLH.  However, additional studies are 
required to determine if this mechanism also promotes germinal center formation and B cell 
memory in response to infection.  Immunization of mice with NP-KLH results in a primarily 
IgG1-mediated antibody response (2).   In contrast, bacterial and viral models of infection can 
produce antibodies of varying antigen specificities and IgG isotypes. For example, LCMV 
infection results in a primarily IgG2a-mediated response. It is possible that infections that 
give rise to antibodies of differing isotypes will highlight the role of additional Fc receptors.  
Preliminary studies with collaborators have demonstrated that B6 and CD16-/- mice mount 
comparable primary and secondary immune responses to LCMV infection, suggesting that 
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CD16 does not play a role in B cell memory responses to LCMV.  Because this infection 
results in a primarily IgG2a mediated response, and CD16 preferentially binds IgG1, it is 
likely that other Fc receptors, particularly CD64, are involved.  Alternatively, in the LCMV 
infection model, additional mechanism may exist (i.e. IFN-α production) to promote BAFF-
induced memory B cell responses.  Thus, future experiments are being designed to address 
the role of CD16 and additional Fc receptors in regulating secondary immune responses to 
infection.  
5.3 Additional factors that induce memory B cell formation by BAFF 
 It must also be considered that the mechanisms by which BAFF regulates B cell 
memory and reactivation may require the priming of B cells by additional factors.  Without 
additional levels of regulation, every B cell encountering BAFF would enter the memory B 
cell pool.  Preliminary studies in our lab demonstrate that repression of B cell Ig secretion in 
vitro by BAFF requires the presence of TGF-b in culture.  TGF-b has been implicated by 
other studies in our lab (Chapter 4) as a regulator of B cell responses in vitro.  Perhaps the 
production of additional cytokines, including TGF-β may also impact BAFF secretion by 
antigen presenting cells.  TGF-β signaling in macrophages is known to induce BAFF 
production (3).  In addition to immune complex binding by Fc receptors, other factors may 
also enhance BAFF production by DCs, that overall, impact B cell responses and adaptive 
immunity. 
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 5.4 Anti-BAFF therapies in the treatment of autoimmune disease 
Historically, the treatment of autoimmune diseases such as SLE has been challenging 
because a balance must be maintained between the efficacy of immunosuppressive agents 
and the adverse side effects of immune suppression.  Our studies have vast implications in 
using anti-BAFF pharmacotherapies to treat SLE and other autoimmune diseases.  BAFF has 
been previously linked to autoimmune-related pathologies in mice and humans.  Studies have 
demonstrated that mice over-expressing BAFF have expanded B cell populations, which 
contribute to spontaneous germinal center development, increased autoantibody titers, 
elevated numbers of effector T cells, and immunoglobulin deposition within the kidney (4).  
BAFF-Tg mice develop a severe autoimmune disease that is similar to SLE and Sjogren’s 
syndrome in humans (4, 5). Thus, it is clear that BAFF overproduction in mice has a 
pathogenic role in autoimmunity by enhancing the survival and activation of autoreactive B 
cells. Additionally, increased levels of BAFF have also been detected in patients with various 
autoimmune conditions, and a correlation with disease progression has frequently been 
observed (6). It remains unclear whether the increased levels of BAFF found in human 
patients are a primary cause of autoimmunity or the result of increased production of pro-
inflammatory cytokines (such as IFN-α), which are known to promote BAFF production (7, 
8).  Our studies would suggest that BAFF has a causative role in the clinical manifestations 
of SLE.  Ongoing studies in our lab show that increased BAFF production by dendritic cells 
and macrophages, induced by pathogenic immune complexes, results in the migration of 
inflammatory cells into target organs and increased disease manifestation in lupus-prone 
mice. Our data reported herein would also suggest that in addition to increased B cell 
survival, excessive BAFF promotes the formation of autoreactive memory B cells, 
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reactivation of those B cells in response to self-antigen during secondary immune responses, 
and finally, the propagation of autoantibody production.  Thus, BAFF may have multiple 
roles in initiating the breakdown in immune tolerance.  
 Within the last year, a BAFF-neutralizing monoclonal antibody, belimumab 
(Benlysta®), received FDA approval as the first new therapeutic to treat SLE in over 50 
years (9, 10).  Its success has been attributed to the depletion of self-reactive B cells, which 
require BAFF for survival.  Depletion of B cells in Benlysta®-treated SLE patients occurs 
predominantly in the naïve and transitional populations, and maximum depletion is reached 
at 6-8 months after starting therapy (6).  In light of our data, the success of anti-BAFF 
therapies could also be attributed to the failure to reactivate memory B cells that respond to 
self-antigens, as well the failure to generate additional self-reactive memory B cells.  
Because autoreactive B cells are chronically exposed to antigen (DNA, histones, Sm, etc.), 
reactivation of self-reactive memory B cells presents a challenge in the treatment of 
autoimmune disease. Studies have shown that memory B cell survival is independent of 
BAFF (11); however, our studies demonstrate that the formation and reactivation of memory 
B cells is dependent on BAFF.  Our work highlighting the importance of BAFF in memory B 
cell formation in mice is supported by studies by Ettinger et al. demonstrating that BAFF and 
IL-21 can synergize to promote the reactivation of human memory B cells (12). Although 
memory B cells can persist following BAFF depletion, our studies herein demonstrate that 
their reactivation is prevented, which may contribute to amelioration of disease in SLE 
patients.  Furthermore, the formation of additional autoreactive memory B cells will also be 
prevented as a consequence of anti-BAFF therapy.  Because BAFF is critical for human 
memory B cell formation and expansion, one must also consider potential side effects of 
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Benlysta® therapy, such as failure to form memory in response to foreign antigens and 
vaccination.  It is likely that any vaccinations (i.e., influenza vaccination) occurring after 
Benlysta® treatment has been initiated may fail to give rise to immunological memory.  
Future studies are needed to assess vaccine efficacy in Benlysta®-treated patients.  
5.5 BAFF may improve vaccine efficacy 
 Most modern, successful vaccines have been developed to neutralize pathogens that 
possess few antigenic variations and cause acute infections, followed by long-term protective 
immunity (13, 14).  Unfortunately, there are several instances where a primary infection does 
not lead to protective immunity, such as infections with highly variable pathogens, including 
dengue virus, influenza virus, HIV-1, and Mycobacterium tuberculosis (15-17).   For 
unknown reasons, clearance of respiratory syncytial virus (RSV) infection is not followed by 
protective immune memory: re-infection with the same virus can occur multiple times (18).  
Other pathogens such as Staphylococcus aureus can evade the immune system and suppress 
the development of protective immunity in the infected host.  It remains unclear why 
infections by these pathogens fail to yield protective immunity and why vaccines that target 
these pathogens have also failed.  In light of our data, the failure to induce protective 
immunity and memory following some infections could occur if immune evasion by the 
pathogen results in failure to form immune complexes and promote BAFF secretion.  
However additional studies are required to determine if Fc binding and BAFF production 
modulates the immune response in these infections.  
 Because of its role in B cell homeostasis, germinal center maintenance, and the 
generation of TFH cells as well as antigen-specific memory B cells, one would also 
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hypothesize that BAFF can be used to improve vaccine strategies.  Indeed, a few studies have 
demonstrated a beneficial role of BAFF in enhancing vaccine protection.  One specific study 
has shown that soluble recombinant BAFF enhanced vaccination against infectious bursal 
disease (IBDV) in chickens (19).  The administration of soluble BAFF has also improved the 
efficacy of an HIV DNA vaccine in mice (20).  An additional study has shown that the 
transient over-expression of BAFF resulted in increased antigen-specific antibody responses 
upon immunization with heat-killed Pseudomonas aeruginosa (21).  Further, over-expression 
of BAFF also enabled immune protection following a lethal secondary challenge with P. 
aeruginosa in mice.  Protective immunity was also improved when BAFF was administered 
four weeks after immunization, demonstrating that the temporary over-expression of BAFF 
can also augment an ongoing immune response following initial exposure to antigen. It is 
important to note that these studies used transient doses of BAFF, as long-term 
administration of BAFF would likely result in autoantibody production and autoimmunity.  
Together these data imply that BAFF may be considered as a molecular vaccine adjuvant that 
could support the induction of antigen-specific protective immune responses to infections in 
which there are currently no successful vaccine regimens. Many experimental vaccines and 
monoclonal antibodies directed against Pseudomonas have been tested in preclinical trials, 
but only a few have reached clinical phases and none has obtained FDA approval (22). BAFF 
may represent an advance towards successful vaccination programs for Pseudomonas 
infection.  Interestingly, the expression of CD16 is also required for protective immunity 
against P. aeruginosa (23).  Thus, both BAFF and CD16 seem to be important key factors in 
mediating immune responses against Pseudomonas infection. Based on our studies, one 
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would predict that by modifying BAFF levels in vivo, memory B cell formation during T-
dependent immune responses could also be modulated to improve vaccine efficacy.  
5.6 The immune system as a target organ system of toxicant action 
There is increasing evidence that chronic exposure to certain toxicants at levels too 
low to be overtly toxic can harm human health by modulating the function of the immune 
system.  Many compounds, including metals, pharmacological agents, and pesticides, are 
able to alter immune function (24).  Additionally, the ability of toxicants to alter host 
resistance to a variety of bacterial and viral challenges suggest that there is a possible role of 
toxicants in increasing morbidity and mortality due to increased susceptibility to infection. 
This increased susceptibility may be the consequence of failure to induce immunological 
memory and protection following pathogen exposure. In addition, toxicant exposure may 
also adversely affect responses to immunization and the ability to initiate secondary immune 
responses. Several compounds have been shown to inhibit T-dependent secondary immune 
responses, including tetraethyl lead, methyl mercury, aflatoxin B1, and 2, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin (TCDD or dioxin) (24).  Although these toxic effects on 
secondary immunity have been observed, the mechanisms of action are still relatively 
undefined. Lead has been shown to inhibit antibody responses by impairing T cell function, 
similar to the effects of both dioxin and aflatoxin (25-27).  Perhaps lead and toxicants with 
similar mechanisms of action impair recall responses indirectly by dampening overall 
antibody production.  Lack of Ig secretion would result in decreased immune complex 
formation and according to our studies, a deficit in DC-derived BAFF production.  Thus 
these toxicants may disrupt secondary immune responses by inhibiting IC-induced BAFF 
production.  A single study has also implicated lead in downregulating the expression of 
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CD16 (28).  This study in conjunction with our data implies that lead may exert its 
immunotoxic effects by limiting IC binding by CD16 and subsequent BAFF production. 
Because of the effects of lead, aflatoxin, and other toxicants on T cell function, one 
would also predict an additional role in modulating other events in the adaptive immune 
response, including germinal center initiation, B and T cell memory generation, and isotype 
switching. More recent studies have further documented the role of toxicant exposure in the 
impairment of secondary immunity and have begun to elucidate the mechanism by which this 
impairment occurs.  Some particular chemicals have generated renewed interest in their 
immunotoxic potential, including lead, dioxin, and fluorinated compounds. A few recent 
studies have demonstrated that dioxin exposure suppresses the formation of germinal centers 
induced by NP-CGG immunization, as well as the high-affinity antibody response (29).  The 
authors assert that the suppression of germinal center formation was most likely due to the 
inhibition of B and T cell proliferation (29).  Perhaps TCDD exposure also results in reduced 
BAFF levels, which, according to our data, could also explain the defect in germinal center 
formation observed in our studies.  Subsequent studies by Lawrence et al. have demonstrated 
that TCDD exposure also impacts long-term immune memory.  Specifically, the authors 
showed that activation of the aryl hydrocarbon (Ah) receptor by TCDD results in a 
diminished secondary immune response to influenza infection (30).  The authors attribute 
this defect to the failure to generate functional CD8+ memory T cells.  Alternatively, the 
effects of dioxin exposure on secondary immune responses could also reflect the impairment 
of the DC’s ability to bind immune complexes and secrete BAFF. Perfluorinated compounds 
(PFCs), such as PFOA and PFOS, can also impact secondary immune responses. Recently, 
the effects of PFC exposure on T-dependent immunity and responses to vaccination have 
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generated much interest (31).  Ongoing studies are necessary to address additional roles of 
environmental toxicants in modulating immune responses.  
Many environmental toxicants that affect the immune system in humans are 
immunosuppressive; however, other chemicals can be pro-inflammatory and contribute to 
autoimmunity. Although genetic predisposition may be a contributing factor for the 
development of spontaneous autoimmune disease, the incomplete concordance in SLE in 
twin studies would suggest that exogenous factors are also important in disease development 
(32, 33).  There are a number of chemicals that clearly impact the immune system and can 
contribute to the exacerbation of autoimmune disease, including organic solvents, such as 
trichloroethylene (TCE), mercury, vinyl chloride, organic solvents, silica, and ultrafine 
particles (34).  Many epidemiological reports and case studies have found that chronic, low-
level exposure to the organic solvent TCE is linked to various autoimmune diseases 
including SLE, scleroderma, bullous pemphigoid, diabetes, and immune-mediated hepatitis 
(35-40). Even if overt disease is not diagnosed, signs of immune activation are evident, 
including increased T cell numbers and elevated levels of serum autoantibody (41, 42).  In 
addition to human studies, mice chronically exposed to TCE showed increased incidence of 
autoimmune hepatitis (43) and increased production of antinuclear antibodies, indicative of 
lupus (44).  Although alterations in T cell function have been implicated in the mode of 
action, the mechanisms by which these chemicals induce autoimmunity remain unclear. 
Perhaps toxicant exposure can modulate BAFF expression and contribute to pathologies 
found in SLE patients.  Future studies are required to address the use of increased serum 
levels of BAFF as a biomarker of toxicant exposure, potentially leading to the onset of the 
breakdown of immune tolerance subsequent autoimmunity. 
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